Le Rézo

'en:complete gene sequence analysis; mlh1 gene'
(id=8087941 ; fe=en:complete gene sequence analysis; mlh1 gene ; type=1 ; niveau=200 ; luminosité=25 ; somme entrante=12169 creation date=2017-07-21 touchdate=2024-09-20 01:03:42.000)

≈ 434 relations sortantes

en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 43 / 1 -> en:injection, ramucirumab, 5 mg administered
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 43 / 1 -> en:most recent ldl-c not under control, results documented and reviewed
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 43 / 1 -> en:patient not treated for spoken language comprehension disorder
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 43 / 1 -> en:surgical pathology, gross and microscopic examination, for prostate needle biopsy, any method, 21-40 specimens
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 42 / 0.977 -> en:follow-up cta, duplex, or mra of the abdomen and pelvis not performed
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 42 / 0.977 -> en:injection, ferric carboxymaltose, 1 mg
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 42 / 0.977 -> en:injection, zoledronic acid (zometa), 1 mg administered
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 41 / 0.953 -> en:assessment of depression severity at the initial evaluation
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 41 / 0.953 -> en:patient not treated for reading disorder
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 41 / 0.953 -> en:patient not treated for writing disorder
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 40 / 0.93 -> en:complete apc gene sequence analysis for susceptibility to familial adenomatous polyposis (fap) and attenuated fap
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 40 / 0.93 -> en:pcp prophylaxis was not prescribed within 3 months oflow cd4+ cell count below 500 cells/mm3 or a cd4 percentage below 15%, reason not given
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 39 / 0.907 -> en:linear accelerator based stereotactic radiosurgery, complete course of therapy in one session
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 38 / 0.884 -> en:antiplatelet medication contraindicated
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 38 / 0.884 -> en:documentation of medical reason(s) for most recent blood pressure not being under control (e.g., patients with palliative goals or for whom treatment of hypertension with standard treatment goals is not clinically appropriate)
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 38 / 0.884 -> en:patient treated for spoken language expression but not scored on the spoken language expression functional communication measure either at admission or at discharge
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 38 / 0.884 -> en:score on the writing functional communication measure at discharge was not higher than at admission, reason not given
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 37 / 0.86 -> en:death, permanent nursing home resident or receiving hospice or palliative care any time during the measurement period
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 37 / 0.86 -> en:injection, human fibrinogen concentrate, 1 mg administered
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 37 / 0.86 -> en:ldl-c was not performed
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 37 / 0.86 -> en:score on the spoken language comprehension functional communication measure at discharge was higher than at admission
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 36 / 0.837 -> en:12-lead electrocardiogram (ecg) not performed, reason not given
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 36 / 0.837 -> en:anti-lipid treatment contraindicated
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 36 / 0.837 -> en:anticoagulation not ordered for reasons documented by clinician
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 36 / 0.837 -> en:anticoagulation ordered
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 36 / 0.837 -> en:autogenous av fistula received
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 36 / 0.837 -> en:beta blocker contraindicated
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 36 / 0.837 -> en:chlorpromazine hydrochloride, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 36 / 0.837 -> en:clinician documented that patient with a diagnosis of major depression was not an eligible candidate for antidepressant medication treatment or patient did not have a diagnosis of major depression
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 36 / 0.837 -> en:colonoscopy, flexible, proximal to splenic flexure; with transendoscopic stent placement (includes predilation)
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 36 / 0.837 -> en:complete brca1 and brca2 gene sequence analysis for susceptibility to breast and ovarian cancer
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 36 / 0.837 -> en:complete gene sequence analysis for hemochromatosis genetic testing
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 36 / 0.837 -> en:documentation of medical reason(s) for not performing ldl-c test (e.g. patients with palliative goals or for whom treatment of hypertension with standard treatment goals is not clinically appropriate)
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 36 / 0.837 -> en:documentation of patient reason(s) for not being able to assess (e.g., patient refuses endoscopic and/or radiologic assessment)
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 36 / 0.837 -> en:documentation of reason(s) for patient not having greater than or equal to 1.2 (single-pool clearance of urea [kt] / volume [v])
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 36 / 0.837 -> en:i intend to report the back pain measures group
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 36 / 0.837 -> en:i intend to report the community-acquired pneumonia (cap) measures group
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 36 / 0.837 -> en:i intend to report the perioperative care measures group
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 36 / 0.837 -> en:influenza a (h1n1) immunization administration (includes the physician counseling the patient/family)
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 36 / 0.837 -> en:injectin, epoetin beta, 1 microgram, (for non esrd use)
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 36 / 0.837 -> en:injection, adenosine for diagnostic use, 30 mg (not to be used to report any adenosine phosphate compounds; instead use a9270)
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 36 / 0.837 -> en:injection, epoetin alfa, 1000 units (for esrd on dialysis) administered
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 36 / 0.837 -> en:injection, morphine sulfate (preservative-free sterile solution), per 10 mg administered
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 36 / 0.837 -> en:injection, oritavancin, 10 mg
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 36 / 0.837 -> en:injection, peginesatide, 0.1 mg (for esrd on dialysis)
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 36 / 0.837 -> en:injection, pembrolizumab, 1 mg
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 36 / 0.837 -> en:injection, siltuximab, 10 mg
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 36 / 0.837 -> en:intraoperative radiation therapy (single administration)
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 36 / 0.837 -> en:lipid profile results documented and reviewed (must include total cholesterol, hdl-c, triglycerides and calculated ldl-c)
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 36 / 0.837 -> en:maternal serum triple marker screen including alpha-fetoprotein (afp), estriol, and human chorionic gonadotropin (hcg)
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 36 / 0.837 -> en:oncology (hepatic), mrna expression levels of 161 genes, utilizing fresh hepatocellular carcinoma tumor tissue, with alpha-fetoprotein level, algorithm reported as a risk classifier
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 36 / 0.837 -> en:patient had a medical visit in the last 6 months
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 36 / 0.837 -> en:patient is not eligible for the referral for otologic evaluation measure
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 36 / 0.837 -> en:patient not receiving a first course of anti-tnf therapy
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 36 / 0.837 -> en:patient not treated for motor speech disorder
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 36 / 0.837 -> en:patient treated for writing but not scored on the writing functional communication measure either at admission or at discharge
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 36 / 0.837 -> en:patients not receiving corticosteroids greater than or equal to 10mg/day for 60 or greater consecutive days
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 36 / 0.837 -> en:pre-hypertensive or hypertensive blood pressure reading documented, indicated follow-up not documented, documentation the patient is not eligible
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 36 / 0.837 -> en:rehabilitation services (occupational, physical or speech) ordered at or prior to discharge
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 36 / 0.837 -> en:score on the memory functional communication measure at discharge was not higher than at admission, reason not given
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 36 / 0.837 -> en:score on the motor speech functional communication measure at discharge was higher than at admission
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 36 / 0.837 -> en:score on the spoken language expression functional communication measure at discharge was higher than at admission
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 36 / 0.837 -> en:score on the spoken language expression functional communication measure at discharge was not higher than at admission, reason not given
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 36 / 0.837 -> en:score on the swallowing functional communication measure at discharge was higher than at admission
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 36 / 0.837 -> en:score on the swallowing functional communication measure at discharge was not higher than at admission, reason not given
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 36 / 0.837 -> en:severity of angina assessed according to level of activity
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 36 / 0.837 -> en:single mutation analysis (in individual with a known brca1 or brca2 mutation in the family) for susceptibility to breast and ovarian cancer
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 36 / 0.837 -> en:transcatheter placement of a drug eluting intracoronary stent(s), percutaneous, with or without other therapeutic intervention, any method; each additional vessel
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 36 / 0.837 -> en:urine protein test result documented and reviewed
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 35 / 0.814 -> en:12-lead electrocardiogram (ecg) performed
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 35 / 0.814 -> en:all quality actions for the applicable measures in the perioperative care measures group have been performed for this patient
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 35 / 0.814 -> en:aneurysm minor diameter >6cm for men
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 35 / 0.814 -> en:anticoagulation was not ordered, reason not given
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 35 / 0.814 -> en:capsaicin 8% patch, per 10 square centimeters
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 35 / 0.814 -> en:colonoscopy, flexible, proximal to splenic flexure; with ablation of tumor(s), polyp(s), or other lesion(s) not amenable to removal by hot biopsy forceps, bipolar cautery or snare technique
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 35 / 0.814 -> en:dicom format image data availability not documented in final report due to medical reasons (eg, ct studies performed for radiation treatment planning or image-guided radiation treatment delivery)
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 35 / 0.814 -> en:direct skilled nursing services of a licensed nurse (lpn or rn) in the home health or hospice setting, each 15 minutes
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 35 / 0.814 -> en:dna analysis of the f5 gene for susceptibility to factor v leiden thrombophilia
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 35 / 0.814 -> en:documentation of medical reason(s) for not counting previous ct and cardiac nuclear medicine (myocardial perfusion) studies (eg, ct studies performed for radiation treatment planning or image-guided radiation treatment delivery)
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 35 / 0.814 -> en:documentation of medical reason(s) for not performing a 12-lead electrocardiogram (ecg)
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 35 / 0.814 -> en:dronabinol, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 35 / 0.814 -> en:duration of monitored anesthesia care (mac) or peripheral nerve block (pnb) without the use of general anesthesia during an applicable procedure 60 minutes or longer, as documented in the anesthesia record
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 35 / 0.814 -> en:female patients with aneurysm minor diameter 5.6-6.0 cm
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 35 / 0.814 -> en:genetic testing, comprehensive cardiac ion channel analysis, for variants in 5 major cardiac ion channel genes for individuals with high index of suspicion for familial long qt syndrome (lqts) or related syndromes
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 35 / 0.814 -> en:i intend to report the cardiovascular prevention measures group
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 35 / 0.814 -> en:ileoscopy,through stoma; with transendoscopic stent placement (includes predilation)
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 35 / 0.814 -> en:implanted pleural catheter, each
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 35 / 0.814 -> en:injection, adenosine for therapeutic use, 6 mg (not to be used to report any adenosine phosphate compounds, instead use a9270)
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 35 / 0.814 -> en:injection, centruroides (scorpion) immune f(ab)2 (equine), 1 vial
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 35 / 0.814 -> en:injection, dalbavancin, 10 mg administered
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 35 / 0.814 -> en:injection, ferric pyrophosphate citrate solution, 0.1 mg of iron
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 35 / 0.814 -> en:injection, testosterone enanthate, up to 100 mg administered
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 35 / 0.814 -> en:injection, zoledronic acid (reclast), 1 mg
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 35 / 0.814 -> en:lipid panel results documented and reviewed (must include total cholesterol, hdl-c, triglycerides and calculated ldl-c)
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 35 / 0.814 -> en:most recent ldl-c >= 100 mg/dl
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 35 / 0.814 -> en:most recent office visit systolic blood pressure <130 mm hg
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 35 / 0.814 -> en:negative pressure ventilator; portable or stationary
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 35 / 0.814 -> en:no beta-blocker at discharge
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 35 / 0.814 -> en:patient encounter was documented using an ehr system that has been certified by an authorized testing and certification body (atcb)
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 35 / 0.814 -> en:patient receiving corticosteroids greater than or equal to 10mg/day for 60 or greater consecutive days
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 35 / 0.814 -> en:patient with a diagnosis of major depression documented as being treated with antidepressant medication during the entire 180 day (6 month) continuation treatment phase
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 35 / 0.814 -> en:patient with a diagnosis of major depression not documented as being treated with antidepressant medication during the entire 180 day (6 months) continuation treatment phase
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 35 / 0.814 -> en:patients who have received dose of corticosteroids greater than or equal to 10mg/day for 60 or greater consecutive days
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 35 / 0.814 -> en:positive airway pressure therapy not prescribed
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 35 / 0.814 -> en:pressure support ventilator with volume control mode, may include pressure control mode, used with invasive interface (e.g., tracheostomy tube)
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 35 / 0.814 -> en:prophylactic parenteral antibiotics were not ordered to be given or given within one hour (if fluoroquinolone or vancomycin, two hours) prior to the surgical incision (or start of procedure when no incision is required), reason not given
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 35 / 0.814 -> en:score on the memory functional communication measure at discharge was higher than at admission
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 35 / 0.814 -> en:score on the motor speech functional communication measure at discharge was not higher than at admission, reason not given
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 35 / 0.814 -> en:spinal orthosis, anterior-posterior-lateral control, with interface material, custom fitted (dewall posture protector only)
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 35 / 0.814 -> en:the eligible professional practices in a rural area without sufficient high speed internet access and requests a hardship exemption from the application of the payment adjustment under section 1848(a)(5)(a) of the social security act
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 35 / 0.814 -> en:the eligible professional practices in an area without sufficient available pharmacies for electronic prescribing and requests a hardship exemption for the application of the payment adjustment under section 1848(a)(5)(a) of the social security act
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 35 / 0.814 -> en:transcarpal/metacarpal or partial hand disarticulation prosthesis, external power, self-suspended, inner socket with removable forearm section, electrodes and cables, two batteries, charger, myoelectric control of terminal device
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 35 / 0.814 -> en:venous thromboembolism (vte) prophylaxis administered the day of or the day after hospital admission
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 35 / 0.814 -> en:volume control ventilator, without pressure support mode, may include pressure control mode, used with non-invasive interface (e.g., mask)
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 34 / 0.791 -> en:all quality actions for the applicable measures in the ischemic vascular disease (ivd) measures group have been performed for this patient
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 34 / 0.791 -> en:assessed level of activity and symptoms
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 34 / 0.791 -> en:blood pressure measurement not documented, reason not given
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 34 / 0.791 -> en:colonoscopy through stoma; with ablation of tumor(s), polyp(s), or other lesion(s) not amenable to removal by hot biopsy forceps, bipolar cautery or snare technique
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 34 / 0.791 -> en:complete gene sequence analysis for cystic fibrosis genetic testing
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 34 / 0.791 -> en:counseling for diet and physical activity not performed, reason not given
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 34 / 0.791 -> en:ct studies not reported to a radiation dose index registry due to medical reasons (eg, ct studies performed for radiation treatment planning or image-guided radiation treatment delivery)
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 34 / 0.791 -> en:diabetes screening test not performed, reason not given
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 34 / 0.791 -> en:documentation of medical reason(s) for not performing diabetes screening test (e.g., patients with a diagnosis of diabetes, or with palliative goals or for whom treatment of hypertension with standard treatment goals is not clinically appropriate)
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 34 / 0.791 -> en:individual who did not fill at least two prescriptions for any antipsychotic medication or did not have a pdc of 0.8 or greater
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 34 / 0.791 -> en:injection, adenosine for diagnostic use, 1 mg (not to be used to report any adenosine phosphate compounds, instead use a9270)
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 34 / 0.791 -> en:injection, aflibercept, 2 mg vial
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 34 / 0.791 -> en:injection, asparaginase erwinia chrysanthemi, 1,000 international units (i.u.)
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 34 / 0.791 -> en:injection, belatacept, 1 mg
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 34 / 0.791 -> en:injection, carfilzomib, 1 mg
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 34 / 0.791 -> en:injection, filgrastim (g-csf), 300 mcg
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 34 / 0.791 -> en:injection, filgrastim (g-csf), 480 mcg
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 34 / 0.791 -> en:injection, interferon beta-1a, 11 mcg for intramuscular use
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 34 / 0.791 -> en:injection, medroxyprogesterone acetate, 50 mg
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 34 / 0.791 -> en:injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 34 / 0.791 -> en:injection, sculptra, 0.1 ml
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 34 / 0.791 -> en:injection, taliglucerase alfa, 10 units
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 34 / 0.791 -> en:injection, testosterone cypionate, 1 cc, 200 mg
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 34 / 0.791 -> en:laparoscopy, surgical, radiofrequency ablations of uterine fibroid(s), including intraoperative guidance and monitoring, when performed
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 34 / 0.791 -> en:ldl value >= 100
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 34 / 0.791 -> en:most recent blood pressure not under control, results documented and reviewed
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 34 / 0.791 -> en:most recent blood pressure under control
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 34 / 0.791 -> en:most recent diastolic blood pressure < 80 mm hg
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 34 / 0.791 -> en:most recent office visit systolic blood pressure >=140 mm hg
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 34 / 0.791 -> en:no anti-lipid treatment at discharge
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 34 / 0.791 -> en:no antiplatelet medication at discharge
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 34 / 0.791 -> en:patch closure not used for patient undergoing conventional cea, reason not specified
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 34 / 0.791 -> en:patient achieves refraction +-1 d for the eye that underwent cataract surgery, measured at the one month follow up visit
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 34 / 0.791 -> en:patient encounter was documented using a pqri qualified ehr or other acceptable systems
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 34 / 0.791 -> en:patient is not eligible for follow-up cta, duplex, or mra (e.g., patient death, failure to return for scheduled follow-up exam, planned follow-up study which will meet numerator criteria has not yet occurred at the time of reporting)
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 34 / 0.791 -> en:patient treated for reading but not scored on the reading functional communication measure either at admission or at discharge
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 34 / 0.791 -> en:patient with a diagnosis of major depression not documented as being treated with antidepressant medication during the entire 84 day (12 week) acute treatment phase
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 34 / 0.791 -> en:pneumococcal conjugate vaccine, polyvalent, intramuscular, for children from five years to nine years of age who have not previously received the vaccine
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 34 / 0.791 -> en:rehabilitation services (occupational, physical or speech) not indicated at or prior to discharge
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 34 / 0.791 -> en:serum creatinine test not performed, reason not given
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 34 / 0.791 -> en:single-mutation analysis (in individual with a known apc mutation in the family) for susceptibility to familial adenomatous polyposis (fap) and attenuated fap
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 34 / 0.791 -> en:skin substitute, endoform dermal template, per square centimeter
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 34 / 0.791 -> en:smoking status and exposure to second hand smoke in the home not assessed, reason not given
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 34 / 0.791 -> en:spkt/v greater than or equal to 1.2 (single-pool clearance of urea [kt] / volume [v])
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 34 / 0.791 -> en:suicide risk not assessed at the initial evaluation, reason not given
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 34 / 0.791 -> en:type, anatomic location, and activity all documented
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 32 / 0.744 -> en:5% dextrose in lactated ringer's, 1000 ml
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 32 / 0.744 -> en:aneurysm minor diameter <= 5.5 cm for women
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 32 / 0.744 -> en:aneurysm minor diameter 5.6-6.0 cm
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 32 / 0.744 -> en:ankle orthosis, ankle gauntlet or similar, with or without joints, a prefabricated, off-the-shelf
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 32 / 0.744 -> en:clinician documented that patient is not an eligible candidate for counseling regarding contraception prior to antiviral treatment; patient not receiving antiviral treatment for hepatitis c
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 32 / 0.744 -> en:clinician documented that patient was not an eligible candidate for antidepressant medication during the entire 12 week acute treatment phase measure
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 32 / 0.744 -> en:colonoscopy through stoma; with transendoscopic stent placement (includes predilation)
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 32 / 0.744 -> en:documentation of medical reason(s) for not performing serum creatinine test (e.g., patients with palliative goals or for whom treatment of hypertension with standard treatment goals is not clinically appropriate)
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 32 / 0.744 -> en:documentation that administration of prophylactic parenteral antibiotics was initiated within one hour (if fluoroquinolone or vancomycin, two hours) prior to surgical incision (or start of procedure when no incision is required), as ordered
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 32 / 0.744 -> en:endoscopic full-thickness plication of the stomach using endoscopic plication system (eps); includes endoscopy
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 32 / 0.744 -> en:everolimus, oral, 0.25 mg
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 32 / 0.744 -> en:fetal aneuploidy (trisomy 21, and 18) dna sequence analysis of selected regions using maternal plasma, algorithm reported as a risk score for each trisomy
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 32 / 0.744 -> en:follow-up cta, duplex, or mra of the abdomen and pelvis performed
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 32 / 0.744 -> en:gene expression profiling panel for use in the management of breast cancer treatment
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 32 / 0.744 -> en:immunohistochemistry or immunocytochemistry, per specimen; each additional single or multiplex antibody stain (list separately in addition to code for primary procedure)
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 32 / 0.744 -> en:injection, aflibercept, 1 mg administered
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 32 / 0.744 -> en:injection, alemtuzumab, 1 mg
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 32 / 0.744 -> en:injection, alemtuzumab, 10 mg administered
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 32 / 0.744 -> en:injection, factor viii fc fusion protein(recombinant), per iu
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 32 / 0.744 -> en:injection, medroxyprogesterone acetate for contraceptive use, 150 mg
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 32 / 0.744 -> en:injection, obinutuzumab, 10 mg
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 32 / 0.744 -> en:injection, omacetaxine mepesuccinate, 0.01 mg
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 32 / 0.744 -> en:injection, pasireotide long acting, 1 mg
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 32 / 0.744 -> en:injection, tedizolid phosphate, 1 mg
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 32 / 0.744 -> en:injection, testosterone cypionate, up to 100 mg
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 32 / 0.744 -> en:injection, vedolizumab, 1 mg administered
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 32 / 0.744 -> en:injection, zoledronic acid, not otherwise specified, 1mg
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 32 / 0.744 -> en:left ventricular ejection fraction (lvef) not performed or assessed, reason not given
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 32 / 0.744 -> en:level of activity and symptoms not assessed
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 32 / 0.744 -> en:levonorgestrel-releasing intrauterine contraceptive system, (skyla), 13.5 mg
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 32 / 0.744 -> en:most current ldl-c >=100mg/dl
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 32 / 0.744 -> en:most recent diastolic blood pressure 80 - 89 mm hg
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 32 / 0.744 -> en:most recent office visit diastolic blood pressure >=90 mm hg
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 32 / 0.744 -> en:most recent systolic blood pressure < 130 mm hg
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 32 / 0.744 -> en:most recent systolic blood pressure >= 140 mm hg
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 32 / 0.744 -> en:netupitant 300 mg and palonosetron 0.5 mg
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 32 / 0.744 -> en:not referred to a physician (preferably a physician with training in disorders of the ear) for an otologic evaluation, reason not given
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 32 / 0.744 -> en:oral aspirin or other antithrombotic therapy prescribed
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 32 / 0.744 -> en:oral aspirin or other antithrombotic therapy was not prescribed, reason not given
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 32 / 0.744 -> en:patch closure used for patient undergoing conventional cea
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 32 / 0.744 -> en:patient continued to have the retina attached at the 6 months follow up visit (+/- 1 month) following only one surgery
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 32 / 0.744 -> en:patient did not have a medical visit in the last 6 months
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 32 / 0.744 -> en:patient documentation - angina assessed as absent
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 32 / 0.744 -> en:patient documentation - most recent ldl-c < 100 mg/dl
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 32 / 0.744 -> en:patient does not achieve refraction +-1 d for the eye that underwent cataract surgery, measured at the one month follow up visit
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 32 / 0.744 -> en:patient not treated for attention disorder
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 32 / 0.744 -> en:patient receiving antiviral treatment for hepatitis c documented
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 32 / 0.744 -> en:patient with a diagnosis of major depression documented as being treated with antidepressant medication during the entire 84 day (12 week) acute treatment phase
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 32 / 0.744 -> en:pregnancy test (urine or serum) ordered
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 32 / 0.744 -> en:pregnancy test (urine or serum) was not ordered, reason not specified
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 32 / 0.744 -> en:pressure support ventilator with volume control mode, may include pressure control mode, used with non-invasive interface (e.g., mask)
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 32 / 0.744 -> en:severity of angina not assessed according to level of activity
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 32 / 0.744 -> en:sigmoidoscopy, flexible; with transendoscopic stent placement (includes predilation)
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 32 / 0.744 -> en:spkt/v less than 1.2 (single-pool clearance of urea [kt] / volume [v]), reason not given
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 32 / 0.744 -> en:suicide risk assessed at the initial evaluation
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 32 / 0.744 -> en:urine protein test was not performed, reason not given
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 32 / 0.744 -> en:volume control ventilator, without pressure support mode, may include pressure control mode, used with invasive interface (e.g., tracheostomy tube)
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 31 / 0.721 -> en:aneurysm minor diameter <= 6 cm for men
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 31 / 0.721 -> en:aneurysm minor diameter >6cm for women
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 31 / 0.721 -> en:ankle orthosis, ankle gauntlet or similar, with or without joints, custom a fabricated
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 31 / 0.721 -> en:anti-lipid treatment at discharge
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 31 / 0.721 -> en:assessment of depression severity not documented, reason not given
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 31 / 0.721 -> en:automated eeg monitoring
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 31 / 0.721 -> en:cd4+ cell count or percentage not documented as performed, reason not given
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 31 / 0.721 -> en:chlorpromazine hydrochloride, 10 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 31 / 0.721 -> en:circulating tumor cell test
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 31 / 0.721 -> en:complete and appropriate patient data were reported to a qualified clinical database registry
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 31 / 0.721 -> en:congestive heart failure telemonitoring, equipment rental, including telescale, computer system and software, telephone connections, and maintenance, per month
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 31 / 0.721 -> en:documentation of medical reason(s) for patient not receiving counseling for diet and physical activity (e.g., patients with palliative goals or for whom treatment of hypertension with standard treatment goals is not clinically appropriate)
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 31 / 0.721 -> en:documentation of patient reason(s) for not performing a 12-lead electrocardiogram (ecg)
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 31 / 0.721 -> en:genetic testing for gaucher disease
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 31 / 0.721 -> en:hemodialysis treatment performed exactly three times per week for > 90 days
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 31 / 0.721 -> en:hepatitis b vaccine injection administered or previously received and is receiving a first course of anti-tnf therapy
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 31 / 0.721 -> en:i intend to report the hypertension (htn) measures group
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 31 / 0.721 -> en:immunohistochemistry or immunocytochemistry, per specimen; first single or multiplex antibody stain
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 31 / 0.721 -> en:individual filled at least two prescriptions for any antipsychotic medication and had a pdc of 0.8 or greater
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 31 / 0.721 -> en:injection, belinostat, 10 mg
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 31 / 0.721 -> en:injection, c-1 esterase inhibitor (recombinant), ruconest, 10 units
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 31 / 0.721 -> en:injection, doxorubicin hydrochloride, all lipid formulations, 10 mg
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 31 / 0.721 -> en:injection, elosulfase alfa, 1 mg
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 31 / 0.721 -> en:injection, epoetin beta, 1 microgram, (for esrd on dialysis)
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 31 / 0.721 -> en:injection, human fibrinogen concentrate, 100 mg
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 31 / 0.721 -> en:injection, medroxyprogesterone acetate / estradiol cypionate, 5mg / 25mg
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 31 / 0.721 -> en:injection, pertuzumab, 10 mg
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 31 / 0.721 -> en:injection, sulfur hexafluoride lipid microsphere, per ml
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 31 / 0.721 -> en:injection, tbo-filgrastim, 5 micrograms
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 31 / 0.721 -> en:left ventricular ejection fraction (lvef) < 40% or documentation of moderately or severely depressed left ventricular systolic function
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 31 / 0.721 -> en:left ventricular ejection fraction (lvef) was not performed or documented
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 31 / 0.721 -> en:most recent diastolic blood pressure >= 90 mm hg
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 31 / 0.721 -> en:most recent ldl-c under control, results documented and reviewed
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 31 / 0.721 -> en:no documentation of disease type, anatomic location, and activity, reason not given
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 31 / 0.721 -> en:oncology (breast), mrna analysis of 58 genes using hybrid capture, on formalin-fixed paraffin-embedded (ffpe) tissue, prognostic algorithm reported as a risk score
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 31 / 0.721 -> en:patient documentation - angina assessed as present
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 31 / 0.721 -> en:patient not treated for memory disorder
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 31 / 0.721 -> en:patient with left ventricular ejection fraction (lvef) >=40% or documentation as normal or mildly depressed left ventricular systolic function
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 31 / 0.721 -> en:portable gaseous oxygen system, rental, includes portable container, regulator, flowmeter, humidifier, cannula or mask, and tubing, for cluster headaches
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 31 / 0.721 -> en:referred to a physician (preferably a physician with training in disorders of the ear) for an otologic evaluation
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 31 / 0.721 -> en:score on the attention functional communication measure at discharge was higher than at admission
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 31 / 0.721 -> en:score on the reading functional communication measure at discharge was higher than at admission
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 31 / 0.721 -> en:spirometry test results demonstrate fev1 >= 60% predicted or patient does not have copd symptoms
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 31 / 0.721 -> en:tissue marker (implantable)
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 31 / 0.721 -> en:vacuum drainage bottle and tubing for use with implanted catheter
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 31 / 0.721 -> en:venous thromboembolism (vte) prophylaxis was not administered the day of or the day after hospital admission, reason not given
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 30 / 0.698 -> en:anoscopy; with directed submucosal injection(s), any substance
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 30 / 0.698 -> en:clinician documented that prostate cancer patient is not an eligible candidate for adjuvant hormonal therapy; low or intermediate risk of recurrence or risk of recurrence not determined
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 30 / 0.698 -> en:documentation of medical reason for not performing foot exam (e.g., patient with bilateral foot/leg amputation)
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 30 / 0.698 -> en:documentation of medical reason(s) for most recent ldl-c not under control (e.g., patients with palliative goals for for whom treatment of hypertension with standard treatment goals is not clinically appropriate)
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 30 / 0.698 -> en:documentation of medical reason(s) for not naming ct studies according to a standardized nomenclature provided (eg, ct studies performed for radiation treatment planning or image-guided radiation treatment delivery)
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 30 / 0.698 -> en:documentation of order for prophylactic parenteral antibiotic to be given within one hour (if fluoroquinolone or vancomycin, two hours) prior to surgical incision (or start of procedure when no incision is required)
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 30 / 0.698 -> en:documentation that prophylactic antibiotics were given within 4 hours prior to surgical incision or intraoperatively
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 30 / 0.698 -> en:each additional cervical vertebral body (list separately in addition to code for primary procedure)
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 30 / 0.698 -> en:epifix, per square centimeter
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 30 / 0.698 -> en:factor ix (antihemophilic factor, recombinant), rixubis, per i.u.
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 30 / 0.698 -> en:genetic testing for canavan disease
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 30 / 0.698 -> en:grafix core, per square centimeter
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 30 / 0.698 -> en:hydroxyzine pamoate, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 30 / 0.698 -> en:i intend to report the ischemic vascular disease (ivd) measures group
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 30 / 0.698 -> en:influenza a (h1n1) vaccine, any route of administration
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 30 / 0.698 -> en:injection, brentuximab vedotin, 1 mg
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 30 / 0.698 -> en:injection, factor viii, fc fusion protein, (recombinant), per i.u.
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 30 / 0.698 -> en:injection, interferon beta-1a, 11 mcg for subcutaneous use
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 30 / 0.698 -> en:injection, paclitaxel, 30 mg administered
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 30 / 0.698 -> en:injection, testosterone cypionate and estradiol cypionate, up to 1 ml
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 30 / 0.698 -> en:injection, testosterone enanthate and estradiol valerate, up to 1 cc administered
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 30 / 0.698 -> en:injection, testosterone propionate, up to 100 mg
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 30 / 0.698 -> en:kras mutation analysis
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 30 / 0.698 -> en:male patients with aneurysms minor diameter >6 cm
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 30 / 0.698 -> en:maternal serum quadruple marker screen including alpha-fetoprotein (afp), estriol, human chorionic gonadotropin (hcg) and inhibin a
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 30 / 0.698 -> en:most recent office visit diastolic blood pressure, <80 mm hg
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 30 / 0.698 -> en:most recent office visit diastolic blood pressure, 80 - 89 mm hg
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 30 / 0.698 -> en:oncology (gastrointestinal neuroendocrine tumors), real-time pcr expression analysis of 51 genes, utilizing whole peripheral blood, algorithm reported as a nomogram of tumor disease index
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 30 / 0.698 -> en:perphenazine, 8mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 30 / 0.698 -> en:prochlorperazine maleate, 10 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 30 / 0.698 -> en:rehabilitation services were not ordered, reason not otherwise specified
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 30 / 0.698 -> en:score on the attention functional communication measure at discharge was not higher than at admission, reason not given
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 30 / 0.698 -> en:score on the reading functional communication measure at discharge was not higher than at admission, reason not given
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 30 / 0.698 -> en:sigmoidoscopy, flexible; with ablation of tumor(s), polyp(s), or other lesions(s) not amenable to removal by hot biopsy forceps, bipolar cautery or snare technique
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 30 / 0.698 -> en:single-mutation analysis (in individual with a known mlh1 and msh2 mutation in the family) for hereditary nonpolyposis colorectal cancer (hnpcc) genetic testing
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 30 / 0.698 -> en:symptomatic patient with ipsilateral stroke or tia within 120 days prior to cea
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 30 / 0.698 -> en:unlisted procedure, intestine
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 29 / 0.674 -> en:abdominal aortic aneurysm is not infarenal
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 29 / 0.674 -> en:adenoma(s) or other neoplasm detected during screening colonoscopy
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 29 / 0.674 -> en:adenoma(s) or other neoplasm not detected during screening colonoscopy
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 29 / 0.674 -> en:all quality actions for the applicable measures in the back pain measures group have been performed for this patient
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 29 / 0.674 -> en:all quality actions for the applicable measures in the epilepsy measures group have been performed for this patient
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 29 / 0.674 -> en:aneurysm minor diameter <= 5.5 cm
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 29 / 0.674 -> en:aneurysm minor diameter 5.6-6.0 cm for women
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 29 / 0.674 -> en:antiplatelet medication at discharge
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 29 / 0.674 -> en:brief office visit for the sole purpose of monitoring or changing drug prescriptions used in the treatment of mental psychoneurotic and personality disorders
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 29 / 0.674 -> en:cd4+ cell count or cd4+ cell percentage results documented
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 29 / 0.674 -> en:clinician documented that patient is receiving antiviral treatment for hepatitis c
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 29 / 0.674 -> en:clinician documented that patient was not an eligible candidate for lower extremity neurological exam measure
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 29 / 0.674 -> en:complete gene sequence analysis; brca1 gene
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 29 / 0.674 -> en:corrugated tubing, non-disposable, used with large volume nebulizer, 10 feet
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 29 / 0.674 -> en:documentation of diagnosis of chronic kidney disease
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 29 / 0.674 -> en:documentation of medical reason(s) for not performing lipid profile (e.g., patients with palliative goals or for whom treatment of hypertension with standard treatment goals is not clinically appropriate)
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 29 / 0.674 -> en:documentation of medical reason(s) for not performing urine protein test (e.g., patients with palliative goals or for whom treatment of hypertension with standard treatment goals is not cllinically appropriate)
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 29 / 0.674 -> en:electronic wrist rotator, otto bock or equal
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 29 / 0.674 -> en:eligible professional does not have prescribing privileges
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 29 / 0.674 -> en:female patients with aneurysm minor diameter >6cm
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 29 / 0.674 -> en:fetal aneuploidy (trisomy 21, 18, and 13) dna sequence analysis of selected regions using maternal plasma, algorithm reported as a risk score for each trisomy
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 29 / 0.674 -> en:fluocinolone acetonide, intravitreal implant
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 29 / 0.674 -> en:genetic testing for detection of mutations in the presenilin - 1 gene
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 29 / 0.674 -> en:genetic testing for tay-sachs disease
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 29 / 0.674 -> en:hcpcs level ii preferred terms, obsolete
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 29 / 0.674 -> en:hemodialysis treatment performed less than three times per week or greater than three times per week
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 29 / 0.674 -> en:hyperbaric oxygen under pressure, full body chamber, per 30 minute interval
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 29 / 0.674 -> en:influenza immunization ordered or recommended (to be given at alternate location or alternate provider); vaccine not available at time of visit
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 29 / 0.674 -> en:injection, ceftolozane 50 mg and tazobactam 25 mg
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 29 / 0.674 -> en:injection, certolizumab pegol, 1 mg
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 29 / 0.674 -> en:injection, doxorubicin hydrochloride, liposomal, doxil, 10 mg
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 29 / 0.674 -> en:injection, isavuconazonium sulfate, 1 mg
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 29 / 0.674 -> en:injection, morphine sulfate, 100mg
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 29 / 0.674 -> en:injection, propofol, 10 mg
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 29 / 0.674 -> en:ldl-c result not present or not within 12 months prior
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 29 / 0.674 -> en:lipid profile not performed, reason not given
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 29 / 0.674 -> en:lvf testing documented as being performed prior to discharge or in the previous 12 months
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 29 / 0.674 -> en:lvf testing not documented as being performed prior to discharge or in the previous 12 months, reason not given
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 29 / 0.674 -> en:mandibular orthopedic repositioning device, each
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 29 / 0.674 -> en:miscellaneous supply or accessory for use with ventricular assist device
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 29 / 0.674 -> en:no documentation of blood pressure measurement, reason not given
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 29 / 0.674 -> en:patient continued to have the retina attached at the 6 months follow up visit (+/- 1 month)
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 29 / 0.674 -> en:patient did not have the retina attached after 6 months following only one surgery
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 29 / 0.674 -> en:patient treated for memory but not scored on the memory functional communication measure either at admission or at discharge
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 29 / 0.674 -> en:patient treated for spoken language comprehension but not scored on the spoken language comprehension functional communication measure either at admission or at discharge
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 29 / 0.674 -> en:patient treated for swallowing but not scored on the swallowing functional communication measure at admission or at discharge
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 29 / 0.674 -> en:pneumocystis jiroveci pneumonia prophlaxis prescribed
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 29 / 0.674 -> en:pregnancy test (urine or serum) not ordered for reasons documented by clinician
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 29 / 0.674 -> en:promethazine hydrochloride, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 29 / 0.674 -> en:score on the writing functional communication measure at discharge was higher than at admission
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 29 / 0.674 -> en:serum creatinine test result documented and reviewed
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 29 / 0.674 -> en:three-mutation brca1 and brca2 analysis for susceptibility to breast and ovarian cancer in ashkenazi individuals
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 29 / 0.674 -> en:total kt/v less than 1.7 per week (total clearance of urea [kt] / volume [v])
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 29 / 0.674 -> en:transcatheter placement of a drug eluting intracoronary stent(s), percutaneous, with or without other therapeutic intervention, any method; single vessel
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 28 / 0.651 -> en:all quality actions for the applicable measures in the cardiovascular prevention measures group have bee performed for this patient
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 28 / 0.651 -> en:all quality actions for the applicable measures in the hypertension (htn) measures group have been performed for this patient
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 28 / 0.651 -> en:anoscopy, high resolution (hra) (with magnification and chemical agent enhancement); diagnostic, including collection of specimen(s) by brushing or washing when performed
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 28 / 0.651 -> en:anoscopy, high resolution (hra) (with magnification and chemical agent enhancement); with biopsy(ies)
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 28 / 0.651 -> en:asymptomatic patient with no history of any transient ischemic attack or stroke in any carotid or vertebrobasilar territory
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 28 / 0.651 -> en:clinician documented that patient recevied vascular access other than autogenous av fistula, reason not given
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 28 / 0.651 -> en:clinician documented that patient was not an eligible candidate for autogenous av fistula
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 28 / 0.651 -> en:counseling for diet and physical activity performed
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 28 / 0.651 -> en:diabetes screening test performed
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 28 / 0.651 -> en:dna analysis, fecal, for colorectal cancer screening
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 28 / 0.651 -> en:drug screen, qualitative; multiple drug classes by high complexity test method (e.g., immunoassay, enzyme assay), per patient encounter
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 28 / 0.651 -> en:electronic wrist rotator, for utah arm
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 28 / 0.651 -> en:factor ix (antihemophilic factor, recombinant), alprolix, per i.u.
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 28 / 0.651 -> en:hemoglobin level measurement not documented, reason not given
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 28 / 0.651 -> en:i intend to report the epilepsy measures group
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 28 / 0.651 -> en:influenza vaccine, recombinant hemagglutinin antigens, for intramuscular use (flublok)
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 28 / 0.651 -> en:injection, immune globulin (bivigam), 500 mg
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 28 / 0.651 -> en:insertion of ocular telescope prosthesis including removal of crystalline lens
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 28 / 0.651 -> en:ldl value < 100
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 28 / 0.651 -> en:ldl-c not performed, reason not given
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 28 / 0.651 -> en:left ventricular ejection fraction (lvef) >= 40% or documentation as normal or mildly depressed left ventricular systolic function
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 28 / 0.651 -> en:levonorgestrel 52mg intrauterine system
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 28 / 0.651 -> en:lvf testing not performed prior to discharge or in the previous 12 months for a medical or patient documented reason
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 28 / 0.651 -> en:most recent hemoglobin (hgb) level > 12.0 g/dl
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 28 / 0.651 -> en:most recent hemoglobin level <= 12.0 g/dl
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 28 / 0.651 -> en:most recent office visit systolic blood pressure, 130 to 139 mm hg
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 28 / 0.651 -> en:most recent systolic blood pressure 130 to 139 mm hg
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 28 / 0.651 -> en:other symptomatic patient with ipsilateral carotid territory tia or stroke > 120 days prior to cea, or contralateral carotid territory tia or stroke or vertebrobasilar tia or stroke
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 28 / 0.651 -> en:patient did not achieve flat retinas six months post surgery
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 28 / 0.651 -> en:patient not receiving maintenance hemodialysis in an outpatient dialysis facility
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 28 / 0.651 -> en:patient not treated for spoken language expression disorder
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 28 / 0.651 -> en:patient receiving hemodialysis, peritoneal dialysis or kidney transplantation
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 28 / 0.651 -> en:patient treated for attention but not scored on the attention functional communication measure either at admission or at discharge
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 28 / 0.651 -> en:prednisone, oral, per 5 mg
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 28 / 0.651 -> en:prostate cancer antigen 3 (pca3) testing
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 28 / 0.651 -> en:score on the spoken language comprehension functional communication measure at discharge was not higher than at admission, reason not given
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 28 / 0.651 -> en:surgical pathology, gross and microscopic examination, for prostate needle biopsy, any method, >60 specimens
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 28 / 0.651 -> en:technetium tc 99m tilmanocept, diagnostic, up to 0.5 millicuries
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 27 / 0.628 -> en:all quality actions for the applicable measures in the community-acquired pneumonia (cap) measures group have been performed for this patient
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 27 / 0.628 -> en:aneurysm minor diameter <= 5.5 cm for men
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 27 / 0.628 -> en:aneurysm minor diameter 5.6-6.0 cm for men
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 27 / 0.628 -> en:beta-blocker at discharge
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 27 / 0.628 -> en:clinician documented that patient did not receive conventional cea
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 27 / 0.628 -> en:complete gene sequence analysis; brca2 gene
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 27 / 0.628 -> en:complete gene sequence analysis; msh2 gene
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 27 / 0.628 -> en:complete mlh1 and msh2 gene sequence analysis for hereditary nonpolyposis colorectal cancer (hnpcc) genetic testing
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 27 / 0.628 -> en:compounded drug, not otherwise classified
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 27 / 0.628 -> en:documentation that prophylactic antibiotics were neither given within 4 hours prior to surgical incision nor intraoperatively
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 27 / 0.628 -> en:drug screen, other than chromatographic; any number of drug classes, by clia waived test or moderate complexity test, per patient encounter
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 27 / 0.628 -> en:duration of monitored anesthesia care (mac) or peripheral nerve block (pnb) without the use of general anesthesia during an applicable procedure or general or neuraxial anesthesia less than 60 minutes, as documented in the anesthesia record
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 27 / 0.628 -> en:factor xiii (antihemophilic factor, recombinant), tretten, per 10 i.u.
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 27 / 0.628 -> en:grafix prime, per square centimeter
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 27 / 0.628 -> en:injection, ado-trastuzumab emtansine, 1 mg
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 27 / 0.628 -> en:injection, blinatumomab, 1 mcg
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 27 / 0.628 -> en:injection, ibuprofen, 100 mg
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 27 / 0.628 -> en:injection, nivolumab, 1 mg
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 27 / 0.628 -> en:injection, ocriplasmin, 0.125 mg
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 27 / 0.628 -> en:injection, peramivir, 1 mg
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 27 / 0.628 -> en:injection, testosterone enanthate, up to 200 mg administered
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 27 / 0.628 -> en:injection, testosterone suspension, up to 50 mg
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 27 / 0.628 -> en:injection, testosterone undecanoate, 1 mg
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 27 / 0.628 -> en:injection, ziv-aflibercept, 1 mg
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 27 / 0.628 -> en:laparoscopy, surgical, esophageal sphincter augmentation with device (e.g., magnetic band)
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 27 / 0.628 -> en:linear accelerator based stereotactic radiosurgery, delivery including collimator changes and custom plugging, fractionated treatment, all lesions, per session, maximum five sessions per course of treatment
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 27 / 0.628 -> en:most current ldl-c <100mg/dl
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 27 / 0.628 -> en:most recent diastolic blood pressure < 90 mmhg
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 27 / 0.628 -> en:most recent diastolic blood pressure >= 90 mmhg
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 27 / 0.628 -> en:most recent systolic blood pressure < 140 mmhg
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 27 / 0.628 -> en:most recent systolic blood pressure >= 140 mmhg
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 27 / 0.628 -> en:patient not treated for swallowing disorder
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 27 / 0.628 -> en:patient treated for motor speech but not scored on the motor speech comprehension functional communication measure either at admission or at discharge
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 27 / 0.628 -> en:patients with a positive hepatitis c antibody test
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 27 / 0.628 -> en:pcp prophylaxis was not prescribed at time of diagnosis of hiv, reason not given
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 27 / 0.628 -> en:percutaneous vertebroplasty, one vertebral body, unilateral or bilateral injection; cervical
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 27 / 0.628 -> en:portable oxygen contents, gaseous, 1 month's supply = 1 unit, for cluster headaches, for initial months supply or to replace used contents
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 27 / 0.628 -> en:prescription(s) generated and transmitted via a qualified erx system
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 27 / 0.628 -> en:surgical pathology, gross and microscopic examination, for prostate needle biopsy, any method, 41-60 specimens
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 27 / 0.628 -> en:total kt/v greater than or equal to 1.7 per week (total clearance of urea [kt] / volume [v])
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 26 / 0.605 -> gène
en:complete gene sequence analysis; mlh1 gene -- r_associated #0: 25 / 0.581 -> en:complete

≈ 433 relations entrantes

en:all quality actions for the applicable measures in the community-acquired pneumonia (cap) measures group have been performed for this patient --- r_associated #0: 43 --> en:complete gene sequence analysis; mlh1 gene
en:prescription(s) generated and transmitted via a qualified erx system --- r_associated #0: 42 --> en:complete gene sequence analysis; mlh1 gene
en:serum creatinine test not performed, reason not given --- r_associated #0: 42 --> en:complete gene sequence analysis; mlh1 gene
en:ankle orthosis, ankle gauntlet or similar, with or without joints, a prefabricated, off-the-shelf --- r_associated #0: 40 --> en:complete gene sequence analysis; mlh1 gene
en:colonoscopy through stoma; with transendoscopic stent placement (includes predilation) --- r_associated #0: 40 --> en:complete gene sequence analysis; mlh1 gene
en:corrugated tubing, non-disposable, used with large volume nebulizer, 10 feet --- r_associated #0: 40 --> en:complete gene sequence analysis; mlh1 gene
en:patient receiving antiviral treatment for hepatitis c documented --- r_associated #0: 40 --> en:complete gene sequence analysis; mlh1 gene
en:injection, ferric carboxymaltose, 1 mg --- r_associated #0: 38 --> en:complete gene sequence analysis; mlh1 gene
en:score on the reading functional communication measure at discharge was not higher than at admission, reason not given --- r_associated #0: 38 --> en:complete gene sequence analysis; mlh1 gene
en:ldl-c was not performed --- r_associated #0: 37 --> en:complete gene sequence analysis; mlh1 gene
en:patient with a diagnosis of major depression not documented as being treated with antidepressant medication during the entire 180 day (6 months) continuation treatment phase --- r_associated #0: 37 --> en:complete gene sequence analysis; mlh1 gene
en:the eligible professional practices in a rural area without sufficient high speed internet access and requests a hardship exemption from the application of the payment adjustment under section 1848(a)(5)(a) of the social security act --- r_associated #0: 37 --> en:complete gene sequence analysis; mlh1 gene
en:colonoscopy, flexible, proximal to splenic flexure; with ablation of tumor(s), polyp(s), or other lesion(s) not amenable to removal by hot biopsy forceps, bipolar cautery or snare technique --- r_associated #0: 36 --> en:complete gene sequence analysis; mlh1 gene
en:documentation of medical reason(s) for not counting previous ct and cardiac nuclear medicine (myocardial perfusion) studies (eg, ct studies performed for radiation treatment planning or image-guided radiation treatment delivery) --- r_associated #0: 36 --> en:complete gene sequence analysis; mlh1 gene
en:dronabinol, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen --- r_associated #0: 36 --> en:complete gene sequence analysis; mlh1 gene
en:drug screen, other than chromatographic; any number of drug classes, by clia waived test or moderate complexity test, per patient encounter --- r_associated #0: 36 --> en:complete gene sequence analysis; mlh1 gene
en:grafix prime, per square centimeter --- r_associated #0: 36 --> en:complete gene sequence analysis; mlh1 gene
en:immunohistochemistry or immunocytochemistry, per specimen; first single or multiplex antibody stain --- r_associated #0: 36 --> en:complete gene sequence analysis; mlh1 gene
en:injection, human fibrinogen concentrate, 100 mg --- r_associated #0: 36 --> en:complete gene sequence analysis; mlh1 gene
en:levonorgestrel 52mg intrauterine system --- r_associated #0: 36 --> en:complete gene sequence analysis; mlh1 gene
en:most recent ldl-c under control, results documented and reviewed --- r_associated #0: 36 --> en:complete gene sequence analysis; mlh1 gene
en:no documentation of disease type, anatomic location, and activity, reason not given --- r_associated #0: 36 --> en:complete gene sequence analysis; mlh1 gene
en:oral aspirin or other antithrombotic therapy was not prescribed, reason not given --- r_associated #0: 36 --> en:complete gene sequence analysis; mlh1 gene
en:patient continued to have the retina attached at the 6 months follow up visit (+/- 1 month) following only one surgery --- r_associated #0: 36 --> en:complete gene sequence analysis; mlh1 gene
en:patient receiving corticosteroids greater than or equal to 10mg/day for 60 or greater consecutive days --- r_associated #0: 36 --> en:complete gene sequence analysis; mlh1 gene
en:patients not receiving corticosteroids greater than or equal to 10mg/day for 60 or greater consecutive days --- r_associated #0: 36 --> en:complete gene sequence analysis; mlh1 gene
en:pregnancy test (urine or serum) not ordered for reasons documented by clinician --- r_associated #0: 36 --> en:complete gene sequence analysis; mlh1 gene
en:score on the reading functional communication measure at discharge was higher than at admission --- r_associated #0: 36 --> en:complete gene sequence analysis; mlh1 gene
en:score on the swallowing functional communication measure at discharge was higher than at admission --- r_associated #0: 36 --> en:complete gene sequence analysis; mlh1 gene
en:score on the writing functional communication measure at discharge was higher than at admission --- r_associated #0: 36 --> en:complete gene sequence analysis; mlh1 gene
en:single-mutation analysis (in individual with a known apc mutation in the family) for susceptibility to familial adenomatous polyposis (fap) and attenuated fap --- r_associated #0: 36 --> en:complete gene sequence analysis; mlh1 gene
en:suicide risk assessed at the initial evaluation --- r_associated #0: 36 --> en:complete gene sequence analysis; mlh1 gene
en:three-mutation brca1 and brca2 analysis for susceptibility to breast and ovarian cancer in ashkenazi individuals --- r_associated #0: 36 --> en:complete gene sequence analysis; mlh1 gene
en:volume control ventilator, without pressure support mode, may include pressure control mode, used with invasive interface (e.g., tracheostomy tube) --- r_associated #0: 36 --> en:complete gene sequence analysis; mlh1 gene
en:volume control ventilator, without pressure support mode, may include pressure control mode, used with non-invasive interface (e.g., mask) --- r_associated #0: 36 --> en:complete gene sequence analysis; mlh1 gene
en:antiplatelet medication contraindicated --- r_associated #0: 35 --> en:complete gene sequence analysis; mlh1 gene
en:complete apc gene sequence analysis for susceptibility to familial adenomatous polyposis (fap) and attenuated fap --- r_associated #0: 35 --> en:complete gene sequence analysis; mlh1 gene
en:documentation of reason(s) for patient not having greater than or equal to 1.2 (single-pool clearance of urea [kt] / volume [v]) --- r_associated #0: 35 --> en:complete gene sequence analysis; mlh1 gene
en:electronic wrist rotator, otto bock or equal --- r_associated #0: 35 --> en:complete gene sequence analysis; mlh1 gene
en:endoscopic full-thickness plication of the stomach using endoscopic plication system (eps); includes endoscopy --- r_associated #0: 35 --> en:complete gene sequence analysis; mlh1 gene
en:i intend to report the community-acquired pneumonia (cap) measures group --- r_associated #0: 35 --> en:complete gene sequence analysis; mlh1 gene
en:injection, alemtuzumab, 10 mg administered --- r_associated #0: 35 --> en:complete gene sequence analysis; mlh1 gene
en:injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg --- r_associated #0: 35 --> en:complete gene sequence analysis; mlh1 gene
en:injection, taliglucerase alfa, 10 units --- r_associated #0: 35 --> en:complete gene sequence analysis; mlh1 gene
en:patient documentation - angina assessed as absent --- r_associated #0: 35 --> en:complete gene sequence analysis; mlh1 gene
en:patients with a positive hepatitis c antibody test --- r_associated #0: 35 --> en:complete gene sequence analysis; mlh1 gene
en:prochlorperazine maleate, 10 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen --- r_associated #0: 35 --> en:complete gene sequence analysis; mlh1 gene
en:score on the attention functional communication measure at discharge was higher than at admission --- r_associated #0: 35 --> en:complete gene sequence analysis; mlh1 gene
en:score on the spoken language comprehension functional communication measure at discharge was higher than at admission --- r_associated #0: 35 --> en:complete gene sequence analysis; mlh1 gene
en:spkt/v greater than or equal to 1.2 (single-pool clearance of urea [kt] / volume [v]) --- r_associated #0: 35 --> en:complete gene sequence analysis; mlh1 gene
en:the eligible professional practices in an area without sufficient available pharmacies for electronic prescribing and requests a hardship exemption for the application of the payment adjustment under section 1848(a)(5)(a) of the social security act --- r_associated #0: 35 --> en:complete gene sequence analysis; mlh1 gene
en:all quality actions for the applicable measures in the epilepsy measures group have been performed for this patient --- r_associated #0: 34 --> en:complete gene sequence analysis; mlh1 gene
en:aneurysm minor diameter >6cm for men --- r_associated #0: 34 --> en:complete gene sequence analysis; mlh1 gene
en:anticoagulation ordered --- r_associated #0: 34 --> en:complete gene sequence analysis; mlh1 gene
en:congestive heart failure telemonitoring, equipment rental, including telescale, computer system and software, telephone connections, and maintenance, per month --- r_associated #0: 34 --> en:complete gene sequence analysis; mlh1 gene
en:documentation of medical reason(s) for most recent blood pressure not being under control (e.g., patients with palliative goals or for whom treatment of hypertension with standard treatment goals is not clinically appropriate) --- r_associated #0: 34 --> en:complete gene sequence analysis; mlh1 gene
en:drug screen, qualitative; multiple drug classes by high complexity test method (e.g., immunoassay, enzyme assay), per patient encounter --- r_associated #0: 34 --> en:complete gene sequence analysis; mlh1 gene
en:duration of monitored anesthesia care (mac) or peripheral nerve block (pnb) without the use of general anesthesia during an applicable procedure or general or neuraxial anesthesia less than 60 minutes, as documented in the anesthesia record --- r_associated #0: 34 --> en:complete gene sequence analysis; mlh1 gene
en:follow-up cta, duplex, or mra of the abdomen and pelvis performed --- r_associated #0: 34 --> en:complete gene sequence analysis; mlh1 gene
en:genetic testing, comprehensive cardiac ion channel analysis, for variants in 5 major cardiac ion channel genes for individuals with high index of suspicion for familial long qt syndrome (lqts) or related syndromes --- r_associated #0: 34 --> en:complete gene sequence analysis; mlh1 gene
en:hcpcs level ii preferred terms, obsolete --- r_associated #0: 34 --> en:complete gene sequence analysis; mlh1 gene
en:injection, adenosine for diagnostic use, 30 mg (not to be used to report any adenosine phosphate compounds; instead use a9270) --- r_associated #0: 34 --> en:complete gene sequence analysis; mlh1 gene
en:injection, belinostat, 10 mg --- r_associated #0: 34 --> en:complete gene sequence analysis; mlh1 gene
en:injection, testosterone cypionate, up to 100 mg --- r_associated #0: 34 --> en:complete gene sequence analysis; mlh1 gene
en:injection, testosterone enanthate, up to 200 mg administered --- r_associated #0: 34 --> en:complete gene sequence analysis; mlh1 gene
en:lipid profile not performed, reason not given --- r_associated #0: 34 --> en:complete gene sequence analysis; mlh1 gene
en:most recent blood pressure under control --- r_associated #0: 34 --> en:complete gene sequence analysis; mlh1 gene
en:oral aspirin or other antithrombotic therapy prescribed --- r_associated #0: 34 --> en:complete gene sequence analysis; mlh1 gene
en:patient treated for swallowing but not scored on the swallowing functional communication measure at admission or at discharge --- r_associated #0: 34 --> en:complete gene sequence analysis; mlh1 gene
en:pcp prophylaxis was not prescribed within 3 months oflow cd4+ cell count below 500 cells/mm3 or a cd4 percentage below 15%, reason not given --- r_associated #0: 34 --> en:complete gene sequence analysis; mlh1 gene
en:pneumocystis jiroveci pneumonia prophlaxis prescribed --- r_associated #0: 34 --> en:complete gene sequence analysis; mlh1 gene
en:rehabilitation services (occupational, physical or speech) not indicated at or prior to discharge --- r_associated #0: 34 --> en:complete gene sequence analysis; mlh1 gene
en:score on the motor speech functional communication measure at discharge was higher than at admission --- r_associated #0: 34 --> en:complete gene sequence analysis; mlh1 gene
en:severity of angina assessed according to level of activity --- r_associated #0: 34 --> en:complete gene sequence analysis; mlh1 gene
en:single mutation analysis (in individual with a known brca1 or brca2 mutation in the family) for susceptibility to breast and ovarian cancer --- r_associated #0: 34 --> en:complete gene sequence analysis; mlh1 gene
en:beta-blocker at discharge --- r_associated #0: 32 --> en:complete gene sequence analysis; mlh1 gene
en:documentation of order for prophylactic parenteral antibiotic to be given within one hour (if fluoroquinolone or vancomycin, two hours) prior to surgical incision (or start of procedure when no incision is required) --- r_associated #0: 32 --> en:complete gene sequence analysis; mlh1 gene
en:factor xiii (antihemophilic factor, recombinant), tretten, per 10 i.u. --- r_associated #0: 32 --> en:complete gene sequence analysis; mlh1 gene
en:genetic testing for canavan disease --- r_associated #0: 32 --> en:complete gene sequence analysis; mlh1 gene
en:genetic testing for gaucher disease --- r_associated #0: 32 --> en:complete gene sequence analysis; mlh1 gene
en:influenza vaccine, recombinant hemagglutinin antigens, for intramuscular use (flublok) --- r_associated #0: 32 --> en:complete gene sequence analysis; mlh1 gene
en:injection, asparaginase erwinia chrysanthemi, 1,000 international units (i.u.) --- r_associated #0: 32 --> en:complete gene sequence analysis; mlh1 gene
en:injection, brentuximab vedotin, 1 mg --- r_associated #0: 32 --> en:complete gene sequence analysis; mlh1 gene
en:injection, sculptra, 0.1 ml --- r_associated #0: 32 --> en:complete gene sequence analysis; mlh1 gene
en:injection, sulfur hexafluoride lipid microsphere, per ml --- r_associated #0: 32 --> en:complete gene sequence analysis; mlh1 gene
en:miscellaneous supply or accessory for use with ventricular assist device --- r_associated #0: 32 --> en:complete gene sequence analysis; mlh1 gene
en:patients who have received dose of corticosteroids greater than or equal to 10mg/day for 60 or greater consecutive days --- r_associated #0: 32 --> en:complete gene sequence analysis; mlh1 gene
en:portable gaseous oxygen system, rental, includes portable container, regulator, flowmeter, humidifier, cannula or mask, and tubing, for cluster headaches --- r_associated #0: 32 --> en:complete gene sequence analysis; mlh1 gene
en:score on the spoken language expression functional communication measure at discharge was higher than at admission --- r_associated #0: 32 --> en:complete gene sequence analysis; mlh1 gene
en:score on the swallowing functional communication measure at discharge was not higher than at admission, reason not given --- r_associated #0: 32 --> en:complete gene sequence analysis; mlh1 gene
en:suicide risk not assessed at the initial evaluation, reason not given --- r_associated #0: 32 --> en:complete gene sequence analysis; mlh1 gene
en:assessed level of activity and symptoms --- r_associated #0: 31 --> en:complete gene sequence analysis; mlh1 gene
en:clinician documented that patient with a diagnosis of major depression was not an eligible candidate for antidepressant medication treatment or patient did not have a diagnosis of major depression --- r_associated #0: 31 --> en:complete gene sequence analysis; mlh1 gene
en:ct studies not reported to a radiation dose index registry due to medical reasons (eg, ct studies performed for radiation treatment planning or image-guided radiation treatment delivery) --- r_associated #0: 31 --> en:complete gene sequence analysis; mlh1 gene
en:documentation of medical reason(s) for not naming ct studies according to a standardized nomenclature provided (eg, ct studies performed for radiation treatment planning or image-guided radiation treatment delivery) --- r_associated #0: 31 --> en:complete gene sequence analysis; mlh1 gene
en:documentation of medical reason(s) for not performing ldl-c test (e.g. patients with palliative goals or for whom treatment of hypertension with standard treatment goals is not clinically appropriate) --- r_associated #0: 31 --> en:complete gene sequence analysis; mlh1 gene
en:injection, adenosine for diagnostic use, 1 mg (not to be used to report any adenosine phosphate compounds, instead use a9270) --- r_associated #0: 31 --> en:complete gene sequence analysis; mlh1 gene
en:injection, pertuzumab, 10 mg --- r_associated #0: 31 --> en:complete gene sequence analysis; mlh1 gene
en:laparoscopy, surgical, esophageal sphincter augmentation with device (e.g., magnetic band) --- r_associated #0: 31 --> en:complete gene sequence analysis; mlh1 gene
en:left ventricular ejection fraction (lvef) not performed or assessed, reason not given --- r_associated #0: 31 --> en:complete gene sequence analysis; mlh1 gene
en:lipid panel results documented and reviewed (must include total cholesterol, hdl-c, triglycerides and calculated ldl-c) --- r_associated #0: 31 --> en:complete gene sequence analysis; mlh1 gene
en:most recent ldl-c not under control, results documented and reviewed --- r_associated #0: 31 --> en:complete gene sequence analysis; mlh1 gene
en:patch closure used for patient undergoing conventional cea --- r_associated #0: 31 --> en:complete gene sequence analysis; mlh1 gene
en:patient encounter was documented using an ehr system that has been certified by an authorized testing and certification body (atcb) --- r_associated #0: 31 --> en:complete gene sequence analysis; mlh1 gene
en:patient not treated for motor speech disorder --- r_associated #0: 31 --> en:complete gene sequence analysis; mlh1 gene
en:patient not treated for reading disorder --- r_associated #0: 31 --> en:complete gene sequence analysis; mlh1 gene
en:pressure support ventilator with volume control mode, may include pressure control mode, used with invasive interface (e.g., tracheostomy tube) --- r_associated #0: 31 --> en:complete gene sequence analysis; mlh1 gene
en:prostate cancer antigen 3 (pca3) testing --- r_associated #0: 31 --> en:complete gene sequence analysis; mlh1 gene
en:rehabilitation services were not ordered, reason not otherwise specified --- r_associated #0: 31 --> en:complete gene sequence analysis; mlh1 gene
en:score on the memory functional communication measure at discharge was not higher than at admission, reason not given --- r_associated #0: 31 --> en:complete gene sequence analysis; mlh1 gene
en:spkt/v less than 1.2 (single-pool clearance of urea [kt] / volume [v]), reason not given --- r_associated #0: 31 --> en:complete gene sequence analysis; mlh1 gene
en:surgical pathology, gross and microscopic examination, for prostate needle biopsy, any method, 21-40 specimens --- r_associated #0: 31 --> en:complete gene sequence analysis; mlh1 gene
en:transcarpal/metacarpal or partial hand disarticulation prosthesis, external power, self-suspended, inner socket with removable forearm section, electrodes and cables, two batteries, charger, myoelectric control of terminal device --- r_associated #0: 31 --> en:complete gene sequence analysis; mlh1 gene
en:unlisted procedure, intestine --- r_associated #0: 31 --> en:complete gene sequence analysis; mlh1 gene
en:aneurysm minor diameter 5.6-6.0 cm for men --- r_associated #0: 30 --> en:complete gene sequence analysis; mlh1 gene
en:anoscopy, high resolution (hra) (with magnification and chemical agent enhancement); diagnostic, including collection of specimen(s) by brushing or washing when performed --- r_associated #0: 30 --> en:complete gene sequence analysis; mlh1 gene
en:anti-lipid treatment at discharge --- r_associated #0: 30 --> en:complete gene sequence analysis; mlh1 gene
en:anticoagulation not ordered for reasons documented by clinician --- r_associated #0: 30 --> en:complete gene sequence analysis; mlh1 gene
en:clinician documented that patient did not receive conventional cea --- r_associated #0: 30 --> en:complete gene sequence analysis; mlh1 gene
en:colonoscopy, flexible, proximal to splenic flexure; with transendoscopic stent placement (includes predilation) --- r_associated #0: 30 --> en:complete gene sequence analysis; mlh1 gene
en:complete and appropriate patient data were reported to a qualified clinical database registry --- r_associated #0: 30 --> en:complete gene sequence analysis; mlh1 gene
en:complete mlh1 and msh2 gene sequence analysis for hereditary nonpolyposis colorectal cancer (hnpcc) genetic testing --- r_associated #0: 30 --> en:complete gene sequence analysis; mlh1 gene
en:diabetes screening test not performed, reason not given --- r_associated #0: 30 --> en:complete gene sequence analysis; mlh1 gene
en:documentation of medical reason(s) for not performing a 12-lead electrocardiogram (ecg) --- r_associated #0: 30 --> en:complete gene sequence analysis; mlh1 gene
en:fluocinolone acetonide, intravitreal implant --- r_associated #0: 30 --> en:complete gene sequence analysis; mlh1 gene
en:hemodialysis treatment performed exactly three times per week for > 90 days --- r_associated #0: 30 --> en:complete gene sequence analysis; mlh1 gene
en:i intend to report the hypertension (htn) measures group --- r_associated #0: 30 --> en:complete gene sequence analysis; mlh1 gene
en:i intend to report the perioperative care measures group --- r_associated #0: 30 --> en:complete gene sequence analysis; mlh1 gene
en:individual filled at least two prescriptions for any antipsychotic medication and had a pdc of 0.8 or greater --- r_associated #0: 30 --> en:complete gene sequence analysis; mlh1 gene
en:influenza a (h1n1) immunization administration (includes the physician counseling the patient/family) --- r_associated #0: 30 --> en:complete gene sequence analysis; mlh1 gene
en:injection, belatacept, 1 mg --- r_associated #0: 30 --> en:complete gene sequence analysis; mlh1 gene
en:injection, epoetin alfa, 1000 units (for esrd on dialysis) administered --- r_associated #0: 30 --> en:complete gene sequence analysis; mlh1 gene
en:injection, morphine sulfate, 100mg --- r_associated #0: 30 --> en:complete gene sequence analysis; mlh1 gene
en:injection, siltuximab, 10 mg --- r_associated #0: 30 --> en:complete gene sequence analysis; mlh1 gene
en:injection, testosterone enanthate and estradiol valerate, up to 1 cc administered --- r_associated #0: 30 --> en:complete gene sequence analysis; mlh1 gene
en:ldl-c not performed, reason not given --- r_associated #0: 30 --> en:complete gene sequence analysis; mlh1 gene
en:most recent diastolic blood pressure 80 - 89 mm hg --- r_associated #0: 30 --> en:complete gene sequence analysis; mlh1 gene
en:patient documentation - angina assessed as present --- r_associated #0: 30 --> en:complete gene sequence analysis; mlh1 gene
en:patient does not achieve refraction +-1 d for the eye that underwent cataract surgery, measured at the one month follow up visit --- r_associated #0: 30 --> en:complete gene sequence analysis; mlh1 gene
en:patient had a medical visit in the last 6 months --- r_associated #0: 30 --> en:complete gene sequence analysis; mlh1 gene
en:patient not receiving maintenance hemodialysis in an outpatient dialysis facility --- r_associated #0: 30 --> en:complete gene sequence analysis; mlh1 gene
en:patient not treated for spoken language expression disorder --- r_associated #0: 30 --> en:complete gene sequence analysis; mlh1 gene
en:positive airway pressure therapy not prescribed --- r_associated #0: 30 --> en:complete gene sequence analysis; mlh1 gene
en:prednisone, oral, per 5 mg --- r_associated #0: 30 --> en:complete gene sequence analysis; mlh1 gene
en:score on the spoken language comprehension functional communication measure at discharge was not higher than at admission, reason not given --- r_associated #0: 30 --> en:complete gene sequence analysis; mlh1 gene
en:spirometry test results demonstrate fev1 >= 60% predicted or patient does not have copd symptoms --- r_associated #0: 30 --> en:complete gene sequence analysis; mlh1 gene
en:tissue marker (implantable) --- r_associated #0: 30 --> en:complete gene sequence analysis; mlh1 gene
en:total kt/v less than 1.7 per week (total clearance of urea [kt] / volume [v]) --- r_associated #0: 30 --> en:complete gene sequence analysis; mlh1 gene
en:type, anatomic location, and activity all documented --- r_associated #0: 30 --> en:complete gene sequence analysis; mlh1 gene
en:5% dextrose in lactated ringer's, 1000 ml --- r_associated #0: 29 --> en:complete gene sequence analysis; mlh1 gene
en:abdominal aortic aneurysm is not infarenal --- r_associated #0: 29 --> en:complete gene sequence analysis; mlh1 gene
en:aneurysm minor diameter 5.6-6.0 cm for women --- r_associated #0: 29 --> en:complete gene sequence analysis; mlh1 gene
en:anoscopy, high resolution (hra) (with magnification and chemical agent enhancement); with biopsy(ies) --- r_associated #0: 29 --> en:complete gene sequence analysis; mlh1 gene
en:beta blocker contraindicated --- r_associated #0: 29 --> en:complete gene sequence analysis; mlh1 gene
en:capsaicin 8% patch, per 10 square centimeters --- r_associated #0: 29 --> en:complete gene sequence analysis; mlh1 gene
en:cd4+ cell count or percentage not documented as performed, reason not given --- r_associated #0: 29 --> en:complete gene sequence analysis; mlh1 gene
en:clinician documented that prostate cancer patient is not an eligible candidate for adjuvant hormonal therapy; low or intermediate risk of recurrence or risk of recurrence not determined --- r_associated #0: 29 --> en:complete gene sequence analysis; mlh1 gene
en:complete gene sequence analysis; brca2 gene --- r_associated #0: 29 --> en:complete gene sequence analysis; mlh1 gene
en:compounded drug, not otherwise classified --- r_associated #0: 29 --> en:complete gene sequence analysis; mlh1 gene
en:documentation of medical reason(s) for patient not receiving counseling for diet and physical activity (e.g., patients with palliative goals or for whom treatment of hypertension with standard treatment goals is not clinically appropriate) --- r_associated #0: 29 --> en:complete gene sequence analysis; mlh1 gene
en:documentation that prophylactic antibiotics were neither given within 4 hours prior to surgical incision nor intraoperatively --- r_associated #0: 29 --> en:complete gene sequence analysis; mlh1 gene
en:factor ix (antihemophilic factor, recombinant), rixubis, per i.u. --- r_associated #0: 29 --> en:complete gene sequence analysis; mlh1 gene
en:female patients with aneurysm minor diameter 5.6-6.0 cm --- r_associated #0: 29 --> en:complete gene sequence analysis; mlh1 gene
en:follow-up cta, duplex, or mra of the abdomen and pelvis not performed --- r_associated #0: 29 --> en:complete gene sequence analysis; mlh1 gene
en:injection, dalbavancin, 10 mg administered --- r_associated #0: 29 --> en:complete gene sequence analysis; mlh1 gene
en:injection, doxorubicin hydrochloride, all lipid formulations, 10 mg --- r_associated #0: 29 --> en:complete gene sequence analysis; mlh1 gene
en:injection, elosulfase alfa, 1 mg --- r_associated #0: 29 --> en:complete gene sequence analysis; mlh1 gene
en:injection, filgrastim (g-csf), 300 mcg --- r_associated #0: 29 --> en:complete gene sequence analysis; mlh1 gene
en:injection, interferon beta-1a, 11 mcg for subcutaneous use --- r_associated #0: 29 --> en:complete gene sequence analysis; mlh1 gene
en:injection, tbo-filgrastim, 5 micrograms --- r_associated #0: 29 --> en:complete gene sequence analysis; mlh1 gene
en:injection, testosterone enanthate, up to 100 mg administered --- r_associated #0: 29 --> en:complete gene sequence analysis; mlh1 gene
en:injection, zoledronic acid (zometa), 1 mg administered --- r_associated #0: 29 --> en:complete gene sequence analysis; mlh1 gene
en:injection, zoledronic acid, not otherwise specified, 1mg --- r_associated #0: 29 --> en:complete gene sequence analysis; mlh1 gene
en:left ventricular ejection fraction (lvef) < 40% or documentation of moderately or severely depressed left ventricular systolic function --- r_associated #0: 29 --> en:complete gene sequence analysis; mlh1 gene
en:lvf testing not performed prior to discharge or in the previous 12 months for a medical or patient documented reason --- r_associated #0: 29 --> en:complete gene sequence analysis; mlh1 gene
en:maternal serum quadruple marker screen including alpha-fetoprotein (afp), estriol, human chorionic gonadotropin (hcg) and inhibin a --- r_associated #0: 29 --> en:complete gene sequence analysis; mlh1 gene
en:most recent hemoglobin (hgb) level > 12.0 g/dl --- r_associated #0: 29 --> en:complete gene sequence analysis; mlh1 gene
en:most recent office visit systolic blood pressure <130 mm hg --- r_associated #0: 29 --> en:complete gene sequence analysis; mlh1 gene
en:most recent systolic blood pressure >= 140 mm hg --- r_associated #0: 29 --> en:complete gene sequence analysis; mlh1 gene
en:no anti-lipid treatment at discharge --- r_associated #0: 29 --> en:complete gene sequence analysis; mlh1 gene
en:patient is not eligible for follow-up cta, duplex, or mra (e.g., patient death, failure to return for scheduled follow-up exam, planned follow-up study which will meet numerator criteria has not yet occurred at the time of reporting) --- r_associated #0: 29 --> en:complete gene sequence analysis; mlh1 gene
en:patient treated for spoken language expression but not scored on the spoken language expression functional communication measure either at admission or at discharge --- r_associated #0: 29 --> en:complete gene sequence analysis; mlh1 gene
en:patient with a diagnosis of major depression documented as being treated with antidepressant medication during the entire 180 day (6 month) continuation treatment phase --- r_associated #0: 29 --> en:complete gene sequence analysis; mlh1 gene
en:patient with a diagnosis of major depression not documented as being treated with antidepressant medication during the entire 84 day (12 week) acute treatment phase --- r_associated #0: 29 --> en:complete gene sequence analysis; mlh1 gene
en:percutaneous vertebroplasty, one vertebral body, unilateral or bilateral injection; cervical --- r_associated #0: 29 --> en:complete gene sequence analysis; mlh1 gene
en:portable oxygen contents, gaseous, 1 month's supply = 1 unit, for cluster headaches, for initial months supply or to replace used contents --- r_associated #0: 29 --> en:complete gene sequence analysis; mlh1 gene
en:single-mutation analysis (in individual with a known mlh1 and msh2 mutation in the family) for hereditary nonpolyposis colorectal cancer (hnpcc) genetic testing --- r_associated #0: 29 --> en:complete gene sequence analysis; mlh1 gene
en:symptomatic patient with ipsilateral stroke or tia within 120 days prior to cea --- r_associated #0: 29 --> en:complete gene sequence analysis; mlh1 gene
en:all quality actions for the applicable measures in the back pain measures group have been performed for this patient --- r_associated #0: 28 --> en:complete gene sequence analysis; mlh1 gene
en:aneurysm minor diameter 5.6-6.0 cm --- r_associated #0: 28 --> en:complete gene sequence analysis; mlh1 gene
en:aneurysm minor diameter >6cm for women --- r_associated #0: 28 --> en:complete gene sequence analysis; mlh1 gene
en:anti-lipid treatment contraindicated --- r_associated #0: 28 --> en:complete gene sequence analysis; mlh1 gene
en:assessment of depression severity at the initial evaluation --- r_associated #0: 28 --> en:complete gene sequence analysis; mlh1 gene
en:clinician documented that patient was not an eligible candidate for autogenous av fistula --- r_associated #0: 28 --> en:complete gene sequence analysis; mlh1 gene
en:clinician documented that patient was not an eligible candidate for lower extremity neurological exam measure --- r_associated #0: 28 --> en:complete gene sequence analysis; mlh1 gene
en:direct skilled nursing services of a licensed nurse (lpn or rn) in the home health or hospice setting, each 15 minutes --- r_associated #0: 28 --> en:complete gene sequence analysis; mlh1 gene
en:documentation of medical reason(s) for most recent ldl-c not under control (e.g., patients with palliative goals for for whom treatment of hypertension with standard treatment goals is not clinically appropriate) --- r_associated #0: 28 --> en:complete gene sequence analysis; mlh1 gene
en:documentation of medical reason(s) for not performing urine protein test (e.g., patients with palliative goals or for whom treatment of hypertension with standard treatment goals is not cllinically appropriate) --- r_associated #0: 28 --> en:complete gene sequence analysis; mlh1 gene
en:i intend to report the back pain measures group --- r_associated #0: 28 --> en:complete gene sequence analysis; mlh1 gene
en:i intend to report the ischemic vascular disease (ivd) measures group --- r_associated #0: 28 --> en:complete gene sequence analysis; mlh1 gene
en:implanted pleural catheter, each --- r_associated #0: 28 --> en:complete gene sequence analysis; mlh1 gene
en:influenza immunization ordered or recommended (to be given at alternate location or alternate provider); vaccine not available at time of visit --- r_associated #0: 28 --> en:complete gene sequence analysis; mlh1 gene
en:injection, isavuconazonium sulfate, 1 mg --- r_associated #0: 28 --> en:complete gene sequence analysis; mlh1 gene
en:injection, medroxyprogesterone acetate, 50 mg --- r_associated #0: 28 --> en:complete gene sequence analysis; mlh1 gene
en:injection, ocriplasmin, 0.125 mg --- r_associated #0: 28 --> en:complete gene sequence analysis; mlh1 gene
en:injection, peginesatide, 0.1 mg (for esrd on dialysis) --- r_associated #0: 28 --> en:complete gene sequence analysis; mlh1 gene
en:injection, propofol, 10 mg --- r_associated #0: 28 --> en:complete gene sequence analysis; mlh1 gene
en:injection, testosterone cypionate, 1 cc, 200 mg --- r_associated #0: 28 --> en:complete gene sequence analysis; mlh1 gene
en:injection, ziv-aflibercept, 1 mg --- r_associated #0: 28 --> en:complete gene sequence analysis; mlh1 gene
en:ldl value >= 100 --- r_associated #0: 28 --> en:complete gene sequence analysis; mlh1 gene
en:left ventricular ejection fraction (lvef) >= 40% or documentation as normal or mildly depressed left ventricular systolic function --- r_associated #0: 28 --> en:complete gene sequence analysis; mlh1 gene
en:left ventricular ejection fraction (lvef) was not performed or documented --- r_associated #0: 28 --> en:complete gene sequence analysis; mlh1 gene
en:level of activity and symptoms not assessed --- r_associated #0: 28 --> en:complete gene sequence analysis; mlh1 gene
en:male patients with aneurysms minor diameter >6 cm --- r_associated #0: 28 --> en:complete gene sequence analysis; mlh1 gene
en:most recent hemoglobin level <= 12.0 g/dl --- r_associated #0: 28 --> en:complete gene sequence analysis; mlh1 gene
en:most recent office visit diastolic blood pressure >=90 mm hg --- r_associated #0: 28 --> en:complete gene sequence analysis; mlh1 gene
en:most recent systolic blood pressure 130 to 139 mm hg --- r_associated #0: 28 --> en:complete gene sequence analysis; mlh1 gene
en:netupitant 300 mg and palonosetron 0.5 mg --- r_associated #0: 28 --> en:complete gene sequence analysis; mlh1 gene
en:patient achieves refraction +-1 d for the eye that underwent cataract surgery, measured at the one month follow up visit --- r_associated #0: 28 --> en:complete gene sequence analysis; mlh1 gene
en:patient is not eligible for the referral for otologic evaluation measure --- r_associated #0: 28 --> en:complete gene sequence analysis; mlh1 gene
en:patient not treated for attention disorder --- r_associated #0: 28 --> en:complete gene sequence analysis; mlh1 gene
en:perphenazine, 8mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen --- r_associated #0: 28 --> en:complete gene sequence analysis; mlh1 gene
en:pregnancy test (urine or serum) was not ordered, reason not specified --- r_associated #0: 28 --> en:complete gene sequence analysis; mlh1 gene
en:promethazine hydrochloride, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen --- r_associated #0: 28 --> en:complete gene sequence analysis; mlh1 gene
en:urine protein test was not performed, reason not given --- r_associated #0: 28 --> en:complete gene sequence analysis; mlh1 gene
en:venous thromboembolism (vte) prophylaxis was not administered the day of or the day after hospital admission, reason not given --- r_associated #0: 28 --> en:complete gene sequence analysis; mlh1 gene
en:aneurysm minor diameter <= 5.5 cm --- r_associated #0: 27 --> en:complete gene sequence analysis; mlh1 gene
en:aneurysm minor diameter <= 5.5 cm for women --- r_associated #0: 27 --> en:complete gene sequence analysis; mlh1 gene
en:blood pressure measurement not documented, reason not given --- r_associated #0: 27 --> en:complete gene sequence analysis; mlh1 gene
en:cd4+ cell count or cd4+ cell percentage results documented --- r_associated #0: 27 --> en:complete gene sequence analysis; mlh1 gene
en:complete brca1 and brca2 gene sequence analysis for susceptibility to breast and ovarian cancer --- r_associated #0: 27 --> en:complete gene sequence analysis; mlh1 gene
en:counseling for diet and physical activity not performed, reason not given --- r_associated #0: 27 --> en:complete gene sequence analysis; mlh1 gene
en:counseling for diet and physical activity performed --- r_associated #0: 27 --> en:complete gene sequence analysis; mlh1 gene
en:documentation of diagnosis of chronic kidney disease --- r_associated #0: 27 --> en:complete gene sequence analysis; mlh1 gene
en:documentation of medical reason(s) for not performing diabetes screening test (e.g., patients with a diagnosis of diabetes, or with palliative goals or for whom treatment of hypertension with standard treatment goals is not clinically appropriate) --- r_associated #0: 27 --> en:complete gene sequence analysis; mlh1 gene
en:electronic wrist rotator, for utah arm --- r_associated #0: 27 --> en:complete gene sequence analysis; mlh1 gene
en:epifix, per square centimeter --- r_associated #0: 27 --> en:complete gene sequence analysis; mlh1 gene
en:fetal aneuploidy (trisomy 21, 18, and 13) dna sequence analysis of selected regions using maternal plasma, algorithm reported as a risk score for each trisomy --- r_associated #0: 27 --> en:complete gene sequence analysis; mlh1 gene
en:hemodialysis treatment performed less than three times per week or greater than three times per week --- r_associated #0: 27 --> en:complete gene sequence analysis; mlh1 gene
en:hydroxyzine pamoate, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen --- r_associated #0: 27 --> en:complete gene sequence analysis; mlh1 gene
en:i intend to report the epilepsy measures group --- r_associated #0: 27 --> en:complete gene sequence analysis; mlh1 gene
en:injection, factor viii, fc fusion protein, (recombinant), per i.u. --- r_associated #0: 27 --> en:complete gene sequence analysis; mlh1 gene
en:injection, medroxyprogesterone acetate / estradiol cypionate, 5mg / 25mg --- r_associated #0: 27 --> en:complete gene sequence analysis; mlh1 gene
en:injection, omacetaxine mepesuccinate, 0.01 mg --- r_associated #0: 27 --> en:complete gene sequence analysis; mlh1 gene
en:intraoperative radiation therapy (single administration) --- r_associated #0: 27 --> en:complete gene sequence analysis; mlh1 gene
en:laparoscopy, surgical, radiofrequency ablations of uterine fibroid(s), including intraoperative guidance and monitoring, when performed --- r_associated #0: 27 --> en:complete gene sequence analysis; mlh1 gene
en:lvf testing documented as being performed prior to discharge or in the previous 12 months --- r_associated #0: 27 --> en:complete gene sequence analysis; mlh1 gene
en:most recent diastolic blood pressure >= 90 mm hg --- r_associated #0: 27 --> en:complete gene sequence analysis; mlh1 gene
en:most recent office visit diastolic blood pressure, 80 - 89 mm hg --- r_associated #0: 27 --> en:complete gene sequence analysis; mlh1 gene
en:no beta-blocker at discharge --- r_associated #0: 27 --> en:complete gene sequence analysis; mlh1 gene
en:oncology (breast), mrna analysis of 58 genes using hybrid capture, on formalin-fixed paraffin-embedded (ffpe) tissue, prognostic algorithm reported as a risk score --- r_associated #0: 27 --> en:complete gene sequence analysis; mlh1 gene
en:patient did not achieve flat retinas six months post surgery --- r_associated #0: 27 --> en:complete gene sequence analysis; mlh1 gene
en:patient not treated for memory disorder --- r_associated #0: 27 --> en:complete gene sequence analysis; mlh1 gene
en:patient treated for reading but not scored on the reading functional communication measure either at admission or at discharge --- r_associated #0: 27 --> en:complete gene sequence analysis; mlh1 gene
en:pcp prophylaxis was not prescribed at time of diagnosis of hiv, reason not given --- r_associated #0: 27 --> en:complete gene sequence analysis; mlh1 gene
en:pneumococcal conjugate vaccine, polyvalent, intramuscular, for children from five years to nine years of age who have not previously received the vaccine --- r_associated #0: 27 --> en:complete gene sequence analysis; mlh1 gene
en:prophylactic parenteral antibiotics were not ordered to be given or given within one hour (if fluoroquinolone or vancomycin, two hours) prior to the surgical incision (or start of procedure when no incision is required), reason not given --- r_associated #0: 27 --> en:complete gene sequence analysis; mlh1 gene
en:technetium tc 99m tilmanocept, diagnostic, up to 0.5 millicuries --- r_associated #0: 27 --> en:complete gene sequence analysis; mlh1 gene
en:transcatheter placement of a drug eluting intracoronary stent(s), percutaneous, with or without other therapeutic intervention, any method; each additional vessel --- r_associated #0: 27 --> en:complete gene sequence analysis; mlh1 gene
en:vacuum drainage bottle and tubing for use with implanted catheter --- r_associated #0: 27 --> en:complete gene sequence analysis; mlh1 gene
en:venous thromboembolism (vte) prophylaxis administered the day of or the day after hospital admission --- r_associated #0: 27 --> en:complete gene sequence analysis; mlh1 gene
en:ankle orthosis, ankle gauntlet or similar, with or without joints, custom a fabricated --- r_associated #0: 26 --> en:complete gene sequence analysis; mlh1 gene
en:anoscopy; with directed submucosal injection(s), any substance --- r_associated #0: 26 --> en:complete gene sequence analysis; mlh1 gene
en:anticoagulation was not ordered, reason not given --- r_associated #0: 26 --> en:complete gene sequence analysis; mlh1 gene
en:antiplatelet medication at discharge --- r_associated #0: 26 --> en:complete gene sequence analysis; mlh1 gene
en:assessment of depression severity not documented, reason not given --- r_associated #0: 26 --> en:complete gene sequence analysis; mlh1 gene
en:autogenous av fistula received --- r_associated #0: 26 --> en:complete gene sequence analysis; mlh1 gene
en:chlorpromazine hydrochloride, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen --- r_associated #0: 26 --> en:complete gene sequence analysis; mlh1 gene
en:clinician documented that patient recevied vascular access other than autogenous av fistula, reason not given --- r_associated #0: 26 --> en:complete gene sequence analysis; mlh1 gene
en:colonoscopy through stoma; with ablation of tumor(s), polyp(s), or other lesion(s) not amenable to removal by hot biopsy forceps, bipolar cautery or snare technique --- r_associated #0: 26 --> en:complete gene sequence analysis; mlh1 gene
en:diabetes screening test performed --- r_associated #0: 26 --> en:complete gene sequence analysis; mlh1 gene
en:genetic testing for detection of mutations in the presenilin - 1 gene --- r_associated #0: 26 --> en:complete gene sequence analysis; mlh1 gene
en:i intend to report the cardiovascular prevention measures group --- r_associated #0: 26 --> en:complete gene sequence analysis; mlh1 gene
en:injection, ado-trastuzumab emtansine, 1 mg --- r_associated #0: 26 --> en:complete gene sequence analysis; mlh1 gene
en:injection, blinatumomab, 1 mcg --- r_associated #0: 26 --> en:complete gene sequence analysis; mlh1 gene
en:injection, centruroides (scorpion) immune f(ab)2 (equine), 1 vial --- r_associated #0: 26 --> en:complete gene sequence analysis; mlh1 gene
en:injection, certolizumab pegol, 1 mg --- r_associated #0: 26 --> en:complete gene sequence analysis; mlh1 gene
en:injection, factor viii fc fusion protein(recombinant), per iu --- r_associated #0: 26 --> en:complete gene sequence analysis; mlh1 gene
en:injection, nivolumab, 1 mg --- r_associated #0: 26 --> en:complete gene sequence analysis; mlh1 gene
en:injection, pembrolizumab, 1 mg --- r_associated #0: 26 --> en:complete gene sequence analysis; mlh1 gene
en:injection, peramivir, 1 mg --- r_associated #0: 26 --> en:complete gene sequence analysis; mlh1 gene
en:injection, zoledronic acid (reclast), 1 mg --- r_associated #0: 26 --> en:complete gene sequence analysis; mlh1 gene
en:insertion of ocular telescope prosthesis including removal of crystalline lens --- r_associated #0: 26 --> en:complete gene sequence analysis; mlh1 gene
en:ldl value < 100 --- r_associated #0: 26 --> en:complete gene sequence analysis; mlh1 gene
en:levonorgestrel-releasing intrauterine contraceptive system, (skyla), 13.5 mg --- r_associated #0: 26 --> en:complete gene sequence analysis; mlh1 gene
en:lipid profile results documented and reviewed (must include total cholesterol, hdl-c, triglycerides and calculated ldl-c) --- r_associated #0: 26 --> en:complete gene sequence analysis; mlh1 gene
en:most current ldl-c >=100mg/dl --- r_associated #0: 26 --> en:complete gene sequence analysis; mlh1 gene
en:no documentation of blood pressure measurement, reason not given --- r_associated #0: 26 --> en:complete gene sequence analysis; mlh1 gene
en:patient did not have a medical visit in the last 6 months --- r_associated #0: 26 --> en:complete gene sequence analysis; mlh1 gene
en:referred to a physician (preferably a physician with training in disorders of the ear) for an otologic evaluation --- r_associated #0: 26 --> en:complete gene sequence analysis; mlh1 gene
en:score on the attention functional communication measure at discharge was not higher than at admission, reason not given --- r_associated #0: 26 --> en:complete gene sequence analysis; mlh1 gene
en:score on the spoken language expression functional communication measure at discharge was not higher than at admission, reason not given --- r_associated #0: 26 --> en:complete gene sequence analysis; mlh1 gene
en:skin substitute, endoform dermal template, per square centimeter --- r_associated #0: 26 --> en:complete gene sequence analysis; mlh1 gene
en:smoking status and exposure to second hand smoke in the home not assessed, reason not given --- r_associated #0: 26 --> en:complete gene sequence analysis; mlh1 gene
en:spinal orthosis, anterior-posterior-lateral control, with interface material, custom fitted (dewall posture protector only) --- r_associated #0: 26 --> en:complete gene sequence analysis; mlh1 gene
en:adenoma(s) or other neoplasm not detected during screening colonoscopy --- r_associated #0: 25 --> en:complete gene sequence analysis; mlh1 gene
en:all quality actions for the applicable measures in the cardiovascular prevention measures group have bee performed for this patient --- r_associated #0: 25 --> en:complete gene sequence analysis; mlh1 gene
en:all quality actions for the applicable measures in the ischemic vascular disease (ivd) measures group have been performed for this patient --- r_associated #0: 25 --> en:complete gene sequence analysis; mlh1 gene
en:aneurysm minor diameter <= 6 cm for men --- r_associated #0: 25 --> en:complete gene sequence analysis; mlh1 gene
en:asymptomatic patient with no history of any transient ischemic attack or stroke in any carotid or vertebrobasilar territory --- r_associated #0: 25 --> en:complete gene sequence analysis; mlh1 gene
en:brief office visit for the sole purpose of monitoring or changing drug prescriptions used in the treatment of mental psychoneurotic and personality disorders --- r_associated #0: 25 --> en:complete gene sequence analysis; mlh1 gene
en:clinician documented that patient is not an eligible candidate for counseling regarding contraception prior to antiviral treatment; patient not receiving antiviral treatment for hepatitis c --- r_associated #0: 25 --> en:complete gene sequence analysis; mlh1 gene
en:complete gene sequence analysis; brca1 gene --- r_associated #0: 25 --> en:complete gene sequence analysis; mlh1 gene
en:dna analysis of the f5 gene for susceptibility to factor v leiden thrombophilia --- r_associated #0: 25 --> en:complete gene sequence analysis; mlh1 gene
en:documentation of medical reason(s) for not performing serum creatinine test (e.g., patients with palliative goals or for whom treatment of hypertension with standard treatment goals is not clinically appropriate) --- r_associated #0: 25 --> en:complete gene sequence analysis; mlh1 gene
en:female patients with aneurysm minor diameter >6cm --- r_associated #0: 25 --> en:complete gene sequence analysis; mlh1 gene
en:grafix core, per square centimeter --- r_associated #0: 25 --> en:complete gene sequence analysis; mlh1 gene
en:injection, alemtuzumab, 1 mg --- r_associated #0: 25 --> en:complete gene sequence analysis; mlh1 gene
en:injection, ceftolozane 50 mg and tazobactam 25 mg --- r_associated #0: 25 --> en:complete gene sequence analysis; mlh1 gene
en:injection, epoetin beta, 1 microgram, (for esrd on dialysis) --- r_associated #0: 25 --> en:complete gene sequence analysis; mlh1 gene
en:injection, ibuprofen, 100 mg --- r_associated #0: 25 --> en:complete gene sequence analysis; mlh1 gene
en:injection, interferon beta-1a, 11 mcg for intramuscular use --- r_associated #0: 25 --> en:complete gene sequence analysis; mlh1 gene
en:injection, obinutuzumab, 10 mg --- r_associated #0: 25 --> en:complete gene sequence analysis; mlh1 gene
en:injection, paclitaxel, 30 mg administered --- r_associated #0: 25 --> en:complete gene sequence analysis; mlh1 gene
en:injection, testosterone undecanoate, 1 mg --- r_associated #0: 25 --> en:complete gene sequence analysis; mlh1 gene
en:kras mutation analysis --- r_associated #0: 25 --> en:complete gene sequence analysis; mlh1 gene
en:most recent diastolic blood pressure < 80 mm hg --- r_associated #0: 25 --> en:complete gene sequence analysis; mlh1 gene
en:most recent office visit diastolic blood pressure, <80 mm hg --- r_associated #0: 25 --> en:complete gene sequence analysis; mlh1 gene
en:most recent systolic blood pressure < 130 mm hg --- r_associated #0: 25 --> en:complete gene sequence analysis; mlh1 gene
en:most recent systolic blood pressure >= 140 mmhg --- r_associated #0: 25 --> en:complete gene sequence analysis; mlh1 gene
en:patient continued to have the retina attached at the 6 months follow up visit (+/- 1 month) --- r_associated #0: 25 --> en:complete gene sequence analysis; mlh1 gene
en:patient not treated for writing disorder --- r_associated #0: 25 --> en:complete gene sequence analysis; mlh1 gene
en:patient treated for attention but not scored on the attention functional communication measure either at admission or at discharge --- r_associated #0: 25 --> en:complete gene sequence analysis; mlh1 gene
en:patient treated for writing but not scored on the writing functional communication measure either at admission or at discharge --- r_associated #0: 25 --> en:complete gene sequence analysis; mlh1 gene
en:pre-hypertensive or hypertensive blood pressure reading documented, indicated follow-up not documented, documentation the patient is not eligible --- r_associated #0: 25 --> en:complete gene sequence analysis; mlh1 gene
en:pressure support ventilator with volume control mode, may include pressure control mode, used with non-invasive interface (e.g., mask) --- r_associated #0: 25 --> en:complete gene sequence analysis; mlh1 gene
en:score on the memory functional communication measure at discharge was higher than at admission --- r_associated #0: 25 --> en:complete gene sequence analysis; mlh1 gene
en:score on the writing functional communication measure at discharge was not higher than at admission, reason not given --- r_associated #0: 25 --> en:complete gene sequence analysis; mlh1 gene
en:serum creatinine test result documented and reviewed --- r_associated #0: 25 --> en:complete gene sequence analysis; mlh1 gene
en:sigmoidoscopy, flexible; with transendoscopic stent placement (includes predilation) --- r_associated #0: 25 --> en:complete gene sequence analysis; mlh1 gene
en:total kt/v greater than or equal to 1.7 per week (total clearance of urea [kt] / volume [v]) --- r_associated #0: 25 --> en:complete gene sequence analysis; mlh1 gene
en:transcatheter placement of a drug eluting intracoronary stent(s), percutaneous, with or without other therapeutic intervention, any method; single vessel --- r_associated #0: 25 --> en:complete gene sequence analysis; mlh1 gene
en:12-lead electrocardiogram (ecg) not performed, reason not given --- r_associated #0: 24 --> en:complete gene sequence analysis; mlh1 gene
en:death, permanent nursing home resident or receiving hospice or palliative care any time during the measurement period --- r_associated #0: 24 --> en:complete gene sequence analysis; mlh1 gene
en:dna analysis, fecal, for colorectal cancer screening --- r_associated #0: 24 --> en:complete gene sequence analysis; mlh1 gene
en:documentation of patient reason(s) for not performing a 12-lead electrocardiogram (ecg) --- r_associated #0: 24 --> en:complete gene sequence analysis; mlh1 gene
en:duration of monitored anesthesia care (mac) or peripheral nerve block (pnb) without the use of general anesthesia during an applicable procedure 60 minutes or longer, as documented in the anesthesia record --- r_associated #0: 24 --> en:complete gene sequence analysis; mlh1 gene
en:hepatitis b vaccine injection administered or previously received and is receiving a first course of anti-tnf therapy --- r_associated #0: 24 --> en:complete gene sequence analysis; mlh1 gene
en:hyperbaric oxygen under pressure, full body chamber, per 30 minute interval --- r_associated #0: 24 --> en:complete gene sequence analysis; mlh1 gene
en:ileoscopy,through stoma; with transendoscopic stent placement (includes predilation) --- r_associated #0: 24 --> en:complete gene sequence analysis; mlh1 gene
en:injection, doxorubicin hydrochloride, liposomal, doxil, 10 mg --- r_associated #0: 24 --> en:complete gene sequence analysis; mlh1 gene
en:injection, human fibrinogen concentrate, 1 mg administered --- r_associated #0: 24 --> en:complete gene sequence analysis; mlh1 gene
en:injection, immune globulin (bivigam), 500 mg --- r_associated #0: 24 --> en:complete gene sequence analysis; mlh1 gene
en:ldl-c result not present or not within 12 months prior --- r_associated #0: 24 --> en:complete gene sequence analysis; mlh1 gene
en:lvf testing not documented as being performed prior to discharge or in the previous 12 months, reason not given --- r_associated #0: 24 --> en:complete gene sequence analysis; mlh1 gene
en:no antiplatelet medication at discharge --- r_associated #0: 24 --> en:complete gene sequence analysis; mlh1 gene
en:oncology (gastrointestinal neuroendocrine tumors), real-time pcr expression analysis of 51 genes, utilizing whole peripheral blood, algorithm reported as a nomogram of tumor disease index --- r_associated #0: 24 --> en:complete gene sequence analysis; mlh1 gene
en:other symptomatic patient with ipsilateral carotid territory tia or stroke > 120 days prior to cea, or contralateral carotid territory tia or stroke or vertebrobasilar tia or stroke --- r_associated #0: 24 --> en:complete gene sequence analysis; mlh1 gene
en:patient did not have the retina attached after 6 months following only one surgery --- r_associated #0: 24 --> en:complete gene sequence analysis; mlh1 gene
en:patient documentation - most recent ldl-c < 100 mg/dl --- r_associated #0: 24 --> en:complete gene sequence analysis; mlh1 gene
en:patient treated for memory but not scored on the memory functional communication measure either at admission or at discharge --- r_associated #0: 24 --> en:complete gene sequence analysis; mlh1 gene
en:surgical pathology, gross and microscopic examination, for prostate needle biopsy, any method, >60 specimens --- r_associated #0: 24 --> en:complete gene sequence analysis; mlh1 gene
en:12-lead electrocardiogram (ecg) performed --- r_associated #0: 23 --> en:complete gene sequence analysis; mlh1 gene
en:adenoma(s) or other neoplasm detected during screening colonoscopy --- r_associated #0: 23 --> en:complete gene sequence analysis; mlh1 gene
en:all quality actions for the applicable measures in the hypertension (htn) measures group have been performed for this patient --- r_associated #0: 23 --> en:complete gene sequence analysis; mlh1 gene
en:complete gene sequence analysis for hemochromatosis genetic testing --- r_associated #0: 23 --> en:complete gene sequence analysis; mlh1 gene
en:dicom format image data availability not documented in final report due to medical reasons (eg, ct studies performed for radiation treatment planning or image-guided radiation treatment delivery) --- r_associated #0: 23 --> en:complete gene sequence analysis; mlh1 gene
en:documentation of patient reason(s) for not being able to assess (e.g., patient refuses endoscopic and/or radiologic assessment) --- r_associated #0: 23 --> en:complete gene sequence analysis; mlh1 gene
en:documentation that administration of prophylactic parenteral antibiotics was initiated within one hour (if fluoroquinolone or vancomycin, two hours) prior to surgical incision (or start of procedure when no incision is required), as ordered --- r_associated #0: 23 --> en:complete gene sequence analysis; mlh1 gene
en:factor ix (antihemophilic factor, recombinant), alprolix, per i.u. --- r_associated #0: 23 --> en:complete gene sequence analysis; mlh1 gene
en:immunohistochemistry or immunocytochemistry, per specimen; each additional single or multiplex antibody stain (list separately in addition to code for primary procedure) --- r_associated #0: 23 --> en:complete gene sequence analysis; mlh1 gene
en:injection, adenosine for therapeutic use, 6 mg (not to be used to report any adenosine phosphate compounds, instead use a9270) --- r_associated #0: 23 --> en:complete gene sequence analysis; mlh1 gene
en:injection, carfilzomib, 1 mg --- r_associated #0: 23 --> en:complete gene sequence analysis; mlh1 gene
en:injection, filgrastim (g-csf), 480 mcg --- r_associated #0: 23 --> en:complete gene sequence analysis; mlh1 gene
en:injection, medroxyprogesterone acetate for contraceptive use, 150 mg --- r_associated #0: 23 --> en:complete gene sequence analysis; mlh1 gene
en:injection, ramucirumab, 5 mg administered --- r_associated #0: 23 --> en:complete gene sequence analysis; mlh1 gene
en:injection, vedolizumab, 1 mg administered --- r_associated #0: 23 --> en:complete gene sequence analysis; mlh1 gene
en:patient not receiving a first course of anti-tnf therapy --- r_associated #0: 23 --> en:complete gene sequence analysis; mlh1 gene
en:patient with a diagnosis of major depression documented as being treated with antidepressant medication during the entire 84 day (12 week) acute treatment phase --- r_associated #0: 23 --> en:complete gene sequence analysis; mlh1 gene
en:severity of angina not assessed according to level of activity --- r_associated #0: 23 --> en:complete gene sequence analysis; mlh1 gene
en:all quality actions for the applicable measures in the perioperative care measures group have been performed for this patient --- r_associated #0: 22 --> en:complete gene sequence analysis; mlh1 gene
en:chlorpromazine hydrochloride, 10 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen --- r_associated #0: 22 --> en:complete gene sequence analysis; mlh1 gene
en:clinician documented that patient is receiving antiviral treatment for hepatitis c --- r_associated #0: 22 --> en:complete gene sequence analysis; mlh1 gene
en:complete gene sequence analysis; msh2 gene --- r_associated #0: 22 --> en:complete gene sequence analysis; mlh1 gene
en:everolimus, oral, 0.25 mg --- r_associated #0: 22 --> en:complete gene sequence analysis; mlh1 gene
en:hemoglobin level measurement not documented, reason not given --- r_associated #0: 22 --> en:complete gene sequence analysis; mlh1 gene
en:individual who did not fill at least two prescriptions for any antipsychotic medication or did not have a pdc of 0.8 or greater --- r_associated #0: 22 --> en:complete gene sequence analysis; mlh1 gene
en:injectin, epoetin beta, 1 microgram, (for non esrd use) --- r_associated #0: 22 --> en:complete gene sequence analysis; mlh1 gene
en:injection, pasireotide long acting, 1 mg --- r_associated #0: 22 --> en:complete gene sequence analysis; mlh1 gene
en:injection, testosterone propionate, up to 100 mg --- r_associated #0: 22 --> en:complete gene sequence analysis; mlh1 gene
en:linear accelerator based stereotactic radiosurgery, complete course of therapy in one session --- r_associated #0: 22 --> en:complete gene sequence analysis; mlh1 gene
en:maternal serum triple marker screen including alpha-fetoprotein (afp), estriol, and human chorionic gonadotropin (hcg) --- r_associated #0: 22 --> en:complete gene sequence analysis; mlh1 gene
en:most current ldl-c <100mg/dl --- r_associated #0: 22 --> en:complete gene sequence analysis; mlh1 gene
en:most recent blood pressure not under control, results documented and reviewed --- r_associated #0: 22 --> en:complete gene sequence analysis; mlh1 gene
en:most recent diastolic blood pressure < 90 mmhg --- r_associated #0: 22 --> en:complete gene sequence analysis; mlh1 gene
en:most recent office visit systolic blood pressure, 130 to 139 mm hg --- r_associated #0: 22 --> en:complete gene sequence analysis; mlh1 gene
en:negative pressure ventilator; portable or stationary --- r_associated #0: 22 --> en:complete gene sequence analysis; mlh1 gene
en:oncology (hepatic), mrna expression levels of 161 genes, utilizing fresh hepatocellular carcinoma tumor tissue, with alpha-fetoprotein level, algorithm reported as a risk classifier --- r_associated #0: 22 --> en:complete gene sequence analysis; mlh1 gene
en:patch closure not used for patient undergoing conventional cea, reason not specified --- r_associated #0: 22 --> en:complete gene sequence analysis; mlh1 gene
en:patient not treated for swallowing disorder --- r_associated #0: 22 --> en:complete gene sequence analysis; mlh1 gene
en:patient receiving hemodialysis, peritoneal dialysis or kidney transplantation --- r_associated #0: 22 --> en:complete gene sequence analysis; mlh1 gene
en:patient treated for motor speech but not scored on the motor speech comprehension functional communication measure either at admission or at discharge --- r_associated #0: 22 --> en:complete gene sequence analysis; mlh1 gene
en:patient with left ventricular ejection fraction (lvef) >=40% or documentation as normal or mildly depressed left ventricular systolic function --- r_associated #0: 22 --> en:complete gene sequence analysis; mlh1 gene
en:score on the motor speech functional communication measure at discharge was not higher than at admission, reason not given --- r_associated #0: 22 --> en:complete gene sequence analysis; mlh1 gene
en:sigmoidoscopy, flexible; with ablation of tumor(s), polyp(s), or other lesions(s) not amenable to removal by hot biopsy forceps, bipolar cautery or snare technique --- r_associated #0: 22 --> en:complete gene sequence analysis; mlh1 gene
en:surgical pathology, gross and microscopic examination, for prostate needle biopsy, any method, 41-60 specimens --- r_associated #0: 22 --> en:complete gene sequence analysis; mlh1 gene
en:aneurysm minor diameter <= 5.5 cm for men --- r_associated #0: 21 --> en:complete gene sequence analysis; mlh1 gene
en:automated eeg monitoring --- r_associated #0: 21 --> en:complete gene sequence analysis; mlh1 gene
en:circulating tumor cell test --- r_associated #0: 21 --> en:complete gene sequence analysis; mlh1 gene
en:clinician documented that patient was not an eligible candidate for antidepressant medication during the entire 12 week acute treatment phase measure --- r_associated #0: 21 --> en:complete gene sequence analysis; mlh1 gene
en:complete gene sequence analysis for cystic fibrosis genetic testing --- r_associated #0: 21 --> en:complete gene sequence analysis; mlh1 gene
en:documentation of medical reason for not performing foot exam (e.g., patient with bilateral foot/leg amputation) --- r_associated #0: 21 --> en:complete gene sequence analysis; mlh1 gene
en:documentation of medical reason(s) for not performing lipid profile (e.g., patients with palliative goals or for whom treatment of hypertension with standard treatment goals is not clinically appropriate) --- r_associated #0: 21 --> en:complete gene sequence analysis; mlh1 gene
en:documentation that prophylactic antibiotics were given within 4 hours prior to surgical incision or intraoperatively --- r_associated #0: 21 --> en:complete gene sequence analysis; mlh1 gene
en:each additional cervical vertebral body (list separately in addition to code for primary procedure) --- r_associated #0: 21 --> en:complete gene sequence analysis; mlh1 gene
en:eligible professional does not have prescribing privileges --- r_associated #0: 21 --> en:complete gene sequence analysis; mlh1 gene
en:fetal aneuploidy (trisomy 21, and 18) dna sequence analysis of selected regions using maternal plasma, algorithm reported as a risk score for each trisomy --- r_associated #0: 21 --> en:complete gene sequence analysis; mlh1 gene
en:gene expression profiling panel for use in the management of breast cancer treatment --- r_associated #0: 21 --> en:complete gene sequence analysis; mlh1 gene
en:genetic testing for tay-sachs disease --- r_associated #0: 21 --> en:complete gene sequence analysis; mlh1 gene
en:influenza a (h1n1) vaccine, any route of administration --- r_associated #0: 21 --> en:complete gene sequence analysis; mlh1 gene
en:injection, aflibercept, 1 mg administered --- r_associated #0: 21 --> en:complete gene sequence analysis; mlh1 gene
en:injection, aflibercept, 2 mg vial --- r_associated #0: 21 --> en:complete gene sequence analysis; mlh1 gene
en:injection, c-1 esterase inhibitor (recombinant), ruconest, 10 units --- r_associated #0: 21 --> en:complete gene sequence analysis; mlh1 gene
en:injection, ferric pyrophosphate citrate solution, 0.1 mg of iron --- r_associated #0: 21 --> en:complete gene sequence analysis; mlh1 gene
en:injection, morphine sulfate (preservative-free sterile solution), per 10 mg administered --- r_associated #0: 21 --> en:complete gene sequence analysis; mlh1 gene
en:injection, oritavancin, 10 mg --- r_associated #0: 21 --> en:complete gene sequence analysis; mlh1 gene
en:injection, tedizolid phosphate, 1 mg --- r_associated #0: 21 --> en:complete gene sequence analysis; mlh1 gene
en:injection, testosterone cypionate and estradiol cypionate, up to 1 ml --- r_associated #0: 21 --> en:complete gene sequence analysis; mlh1 gene
en:injection, testosterone suspension, up to 50 mg --- r_associated #0: 21 --> en:complete gene sequence analysis; mlh1 gene
en:linear accelerator based stereotactic radiosurgery, delivery including collimator changes and custom plugging, fractionated treatment, all lesions, per session, maximum five sessions per course of treatment --- r_associated #0: 21 --> en:complete gene sequence analysis; mlh1 gene
en:mandibular orthopedic repositioning device, each --- r_associated #0: 21 --> en:complete gene sequence analysis; mlh1 gene
en:most recent diastolic blood pressure >= 90 mmhg --- r_associated #0: 21 --> en:complete gene sequence analysis; mlh1 gene
en:most recent ldl-c >= 100 mg/dl --- r_associated #0: 21 --> en:complete gene sequence analysis; mlh1 gene
en:most recent office visit systolic blood pressure >=140 mm hg --- r_associated #0: 21 --> en:complete gene sequence analysis; mlh1 gene
en:most recent systolic blood pressure < 140 mmhg --- r_associated #0: 21 --> en:complete gene sequence analysis; mlh1 gene
en:not referred to a physician (preferably a physician with training in disorders of the ear) for an otologic evaluation, reason not given --- r_associated #0: 21 --> en:complete gene sequence analysis; mlh1 gene
en:patient encounter was documented using a pqri qualified ehr or other acceptable systems --- r_associated #0: 21 --> en:complete gene sequence analysis; mlh1 gene
en:patient not treated for spoken language comprehension disorder --- r_associated #0: 21 --> en:complete gene sequence analysis; mlh1 gene
en:patient treated for spoken language comprehension but not scored on the spoken language comprehension functional communication measure either at admission or at discharge --- r_associated #0: 21 --> en:complete gene sequence analysis; mlh1 gene
en:pregnancy test (urine or serum) ordered --- r_associated #0: 21 --> en:complete gene sequence analysis; mlh1 gene
en:rehabilitation services (occupational, physical or speech) ordered at or prior to discharge --- r_associated #0: 21 --> en:complete gene sequence analysis; mlh1 gene
en:urine protein test result documented and reviewed --- r_associated #0: 21 --> en:complete gene sequence analysis; mlh1 gene
gène --- r_associated #0: 20 --> en:complete gene sequence analysis; mlh1 gene